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Abstract 
Introduction:  
Despite advances in the surgical management of pancreatic cancer, particularly adjuvant 
chemotherapy, pancreatic cancer continues to carry a dismal prognosis. Nanotechnology offers 
the possibility for patient tailored therapy while providing novel methods of targeted drug 
delivery. Our aim was to develop a superparamagnetic iron oxide nanoparticle capable of 
targeted release of chemotherapy in pancreatic cancer cell lines using either specific antibodies 
or through exploitation of their superparamagnetic properties, both in static and dynamic in 
vitro models. 
 
Methodology: 
Micellar superparamagnetic iron oxide nanoparticles, incorporating a gemcitabine pro-drug, 
conjugated to anti-carbohydrate antigen 19-9 antibodies were manufactured using a self-
assembly methodology. Cellular uptake was assessed using co-localisation fluorescent 
microscopy. Antigen expression of cell lines was determined using indirect 
immunofluorescence. Antibody targeting was assessed using EZ4U cytotoxicity assay in Bx 
PC-3 (anti-carbohydrate antigen 19-9 antigen expressive) and Mia Pa Ca-2 (non-anti-
carbohydrate antigen 19-9 expressive) cell lines.  
Complete RPMI media was circulated through custom-made 25cm2 flasks containing 2x106 
monolayers of Mia Pa Ca-2 cells at 37oC/5%CO2. Cells were subjected to control media or 2% 
gemcitabine-loaded superparamagnetic iron oxide nanoparticles, with or without a magnet for 
16/24/48/72 hours. Light and fluorescent microscopy was used to visualise the monolayer and 
gemcitabine-loaded SPION uptake. LDH assay was performed as a measure of cell lysis. 
 
Results:  
The 50% inhibitory concentration of superparamagnetic iron oxide nanoparticles conjugated to 
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anti-carbohydrate antigen 19-9 antibodies was significantly improved with specific antibody 
targeting in BxPC-3 cells (354nM vs 1,175nM) but absent in MiaPaCa-2 cells (3,510nM vs 
3,090nM).  
Light microscopy confirmed destruction of monolayers and co-localisation fluorescent 
microscopy, after up to 72 hours of flow, showed cellular uptake of rhodamine-tagged 
gemcitabine-loaded SPIONs, especially adjacent to a magnet. Lactate dehydrogenase  assay 
optical densities were higher, indicating increased cell lysis, in flow systems subjected to 
gemcitabine-loaded SPIONs with use of a magnet: 16 hours (0.751 v 0.139nm; p<0.001); 24  
hours (0.798 v 0.226; p<0.05); 48 hours (1.716 v 1.375; p=0.01) and 72 hours (1.645 v 1.330; 
p=0.11). There was no significant difference in corresponding static experiments. 
 
Conclusions:  
We have developed a novel nanohybrid to target antigen expressing pancreatic cancer cells 
using a specific antibody tag. When loaded with modified gemcitabine, these SPIONs act as 
delivery vehicles capable of intracellular drug release. They can be successfully drawn from 
circulation and destroy monolayers within a flow system. Magnetic targeting provides greatest 
improvements over static conditions at early time points and is still superior at 72 hours. Bio-
magnetic targeting in custom-made nano-vehicles provides a potential novel theranostic 
solution in pancreatic cancer. This could reduce off target effects leading to increased 
chemotherapy agent efficacy and offer the prospect for new treatments in pancreatic cancer. 
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1. Introduction 
1.1 Nanotechnology and Nanomedicine 
Nanotechnology is rapidly developing; its uses are wide-ranging and provide novel approaches 
in all areas of science. It is the branch of science and engineering that studies and exploits the 
unique behaviour of materials at a scale of approximately 1-100 nanometres [1]. It promises 
huge potential in fields as diverse as healthcare, IT and energy generation and storage.  
Nanomedicine is the application of nanotechnology to achieve breakthroughs exclusively in 
healthcare. It exploits the improved and often novel physical, chemical, and biological 
properties of materials at the nanoscale, and offers the potential to enable early detection, 
prevention, improved diagnosis and imaging, treatment and follow-up of diseases. 
Nanomedicine embraces a wide range of applications from in vivo and in vitro diagnostics to 
therapy including targeted delivery and regenerative medicine [2]. It has the potential to have 
far-reaching benefits in diseases such cancer, diabetics, cardiovascular diseases, multiple 
sclerosis, Alzheimer's and Parkinson's disease and inflammatory and/or infectious diseases, and 
impact individuals and their families. Given the immense potential impact of nanomedicine on 
public well-being and on economic growth, large sums of money are funded towards research 
projects in nanomedicine. The  European Technology Platform on Nanomedicine [3], 
supported by the European Union, has pledged €550 million in 116 projects involving 
nanomedicine advances, through its through its 7th Framework Programme for Research and 
Development (FP7) until 2020 [1].  
1.1.1 Applications of Nanomedicine in Oncology 
Cancer is a leading cause of death worldwide, accounting for 9.6 million deaths (around 13% 
of all deaths) in 2018 with global deaths from cancer projected to continue rising, with an 
estimated 13.1 million deaths in 2030 [4-6]. More than 90% of cancer-related deaths are 
attributed to metastasis. Research advances in nanomedicine are centred to the development of 
specific treatments that can detect and destroy primary and secondary (i.e. metastasis) tumours. 
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Nanomedicine holds the wide-ranging possibilities from earlier diagnostics and improved 
imaging to better, more efficient, and more targeted therapies [3]. The use of nanomaterials to 
treat and image cancer is arguably the most active area of nanomedicine research. As a nascent 
and emerging field that holds great potential for precision oncology, nanotechnology has been 
envisioned to improve drug delivery and imaging capabilities through precise and efficient 
tumour targeting, safely sparing healthy normal tissue. In the clinic, nanoparticle formulations 
such as the first-generation Abraxane® in breast and metastatic pancreatic cancer have shown 
advancement in drug delivery while improving safety profiles [7], [1]. However, effective 
accumulation of nanoparticles at the tumour site is sub-optimal due to biological barriers that 
must be overcome. Nanoparticle delivery and retention can be altered through systematic 
design considerations in order to enhance passive accumulation or active targeting to the 
tumour site. In tumours where passive targeting is possible, modifications in the size and charge 
of nanoparticles play a role in their tissue accumulation. For tumours in which active targeting 
is required, precision oncology research has identified targetable biomarkers, with which 
nanoparticle design can be altered through bioconjugation using antibodies, peptides, or small 
molecule agonists and antagonists [1, 7-9].    
1.1.2 Nanomedicine in cancer imaging 
Properties of certain nanomaterials can be harnessed to improve the resolution and accuracy of 
mapping lesions. Consequently, surgeons can thus rely on this to appropriately select patients 
and plan the surgical removal of a tumour. This has been demonstrated mainly by manipulating 
the magnetic qualities of certain nanomaterials in the use of imaging tumours with magnetic 
resonance [10, 11]. 
1.1.3 The use of nanoparticles in drug delivery in cancer treatment 
Due to their small size and surface area characteristics, they exhibit unique electronic, optical, 
and magnetic properties that can be exploited for drug delivery [12]. It is ideal in cancer therapy 
that anti-cancer therapeutic compounds are delivered to targeted tumour cells to exert their 
effects. Conventional chemotherapy agents that are administered systemically are distributed 
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throughout the body via the bloodstream and are subjected to hydrolysis and enzymatic 
degradation, subsequently leading to rapid excretion through the urinary system. Furthermore, 
owing to suboptimal targeting, the accumulation of the chemotherapeutic agent in tumour cells 
is limited. Targeted delivery of drug molecules with nanoparticles can improve biodistribution, 
increase circulation half-life, and protect drugs from the microenvironment, thus increasing 
efficacy and reducing side effects [13]. Nanoparticles, through the enhanced permeability and 
retention (EPR) effect, preferentially accumulate in tumours [14, 15]. This phenomenon can 
translate into higher therapeutic efficacy and lower toxicity for nanoparticle therapeutics, as 
shown in Gradisher et al. study of conventional versus nanoparticle-based paclitaxel delivery 
in metastatic breast cancer. [16]. Even though nanomedicine is a relatively new branch of 
science, many novel nanoparticle drug delivery platforms have been developed over the past 
three decades. These platforms generally fall into the following categories: liposomes, 
nanoparticle albumin bound (nab) technology, polymeric nanoparticles, dendrimers, metal 
nanoparticles, and molecular targeted nanoparticles. [17]. This thesis will focus on the use of 
metal-based nanoparticles, focusing on iron oxide core nanoparticles. 
1.1.4 Targeting of cancer using nanomaterials 
Nanotechnology offers many possibilities for targeting cancer, as there are several differing 
materials available combined with the ability to construct tailor-made particles to address a 
specific function. Nanoparticles can be synthesised to encapsulate and deliver a diverse range 
of therapeutic compounds, including chemotherapy agents and DNA/RNA. Therefore, specific 
targeting should allow a higher concentration of a nanoparticle to accumulate within the vicinity 
of the tumour and hence reduces systemic side effects of conventional chemotherapy [11]. 
Broadly there are two methods for targeted drug delivery using nanoparticles: passive and 
active. Passive targeting takes advantage of the leaky vasculature of tumours. Due to the small 
size of the nanomaterial, it is thought to preferentially accumulate at the site of the tumour, a 
phenomenon known as the enhanced permeability retention effect. Libutti et al have 
demonstrated in a phase I clinical trial that a novel PEGylated colloidal gold nanoparticle 
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carrying recombinant human tumor necrosis factor alpha (rhTNF), when injected intravenously 
in patients with advance breast cancer, may be administered systemically at doses of rhTNF 
that were previously shown to be toxic. Furthermore, even at the highest dose rhTNF's dose-
limiting toxic effect of hypotension was not seen. This demonstrated increased tumour 
accumulation without the systemic side effects [18]. Active targeting of cancer is facilitated by 
conjugation of the particle with a specific ligand (e.g. antibody) or an external stimulus to guide 
the nanoparticle to the desired location, for example, a magnetic field to direct nanomaterials 
with magnetism.  
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Nanomaterial Key features Potential Use 
Iron oxide Superparamagnetism, (magnetised only in the presence of 
an external magnetic field, termed SPIONs). 
Targeting (accumulation using an external magnetic field to the 
desired site). 
Treatment as alternating magnetic field causes the particles to heat 
up, resulting in thermal ablation of adjacent cells. 
Imaging (MRI contrast). 
Gold Affinity for binding thiols, disulphides, phosphates and 
amines allow simple conjugation with peptides, proteins, 
and antibodies. 
Biological applications as use in targeted cancer therapy. 
Photothermal treatment to ablate specific tissue. 
Quantum dots Fluorescence. Imaging in vivo. 
Nanocarrier for drug delivery. 
Multimodal probe to monitor the biodistribution of drugs. 
Carbon Chemically stable.  
High tensile strength and conductivity. 
Numerous points of attachment, allowing for precise 
grafting of active chemical groups. 
Drug delivery. 
Thermal ablation therapy. 
Liposomes  Lipid vesicles either unilamellar or multilamellar with an 
aqueous compartment 
Structure allows for delivery of a cargo loaded in the 
aqueous compartment or embedded in the lipid bilayer  
Therapy  
Imaging 
Dendrimers  Three dimensional, hyperbranched globular 
nanopolymeric architectures 
Narrow polydispersity index, control over molecular 
structure and availability of multiple functional groups at 
the periphery and cavities 
Terminal functionalities provide a platform for tailor 
made conjugation of drug and targeting moieties 
Drug targeting and delivery 
MRI contrast agents 
Table 1:  Summary of commonly used nanomaterials in oncological applications. (SPIONs: superparamagnetic iron oxide nanoparticles; MRI: magnetic resonance imaging.
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1.2 Superparamagnetic iron oxide nanoparticles 
Superparamagnetic iron oxide nanoparticles (SPIONs) are small synthetic γ-Fe2O3 
(maghemite), Fe3O4 (magnetite) or α-Fe2O3 (hermatite) particles with a core diameter ranging 
from 10 to 100nm. Mixed oxides of iron with transition metal ions such as copper, cobalt, 
nickel, and manganese, are known to exhibit superparamagnetic properties and fall into the 
category of SPIONs [12, 19, 20]. However, magnetite and maghemite nanoparticles are the 
most widely used SPIONs in various biomedical applications. SPIONs have an organic or 
inorganic coating, on or within which a drug is loaded, and they are then can guided by an 
external magnet to their target tissue. This thesis will focus on the relevant biomedical aspects 
of SPIONs rather than the material chemistry processes used in their manufacture. 
1.2.1 Superparamagnetism 
SPIONs exhibit the phenomenon of superparamagnetism, that is, on application of an external 
magnetic field, they become magnetised up to their saturation magnetisation then, on removal 
of the magnetic field, they no longer exhibit any residual magnetic interaction. This property is 
size-dependent and generally arises when the size of nanoparticles is as low as 10 to 20nm [21]. 
This superparamagnetism, unique to nanoparticles, is very important for their use as drug 
delivery vehicles because these nanoparticles can literally drag drug molecules to their target 
site in the body under the influence of an applied magnet field [12]. As described above, once 
the applied magnetic field is removed, the magnetic particles retain no residual magnetism (at 
room temperature) and hence are likely to easily disperse, thus preventing uptake by phagocytes 
and increasing their circulatory half-life. Furthermore, due to a negligible tendency to 
agglomerate, SPIONs pose no danger of thrombosis or blockage of blood capillaries [12, 19, 
20]. 
1.2.2 Size 
The size of nanoparticles largely determines their half-life in the circulation. Particles with sizes 
smaller than 10 nm are mainly removed by renal clearance, whereas particles larger than 200nm 
become concentrated in the spleen or are taken up by phagocytic cells of the body, in both 
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instances leading to decreased plasma concentrations [22]. However, particles with a size range 
of 10 to100nm are considered to be optimal, as they can easily escape the reticuloendothelial 
system and sustain longer circulation times. They are also able to penetrate through very small 
capillaries [12, 23].  The small size of SPIONs is responsible for the enhanced permeability and 
retention (EPR) effect, which causes concentration of the particles in target tumour tissue. 
SPIONs with a particle size smaller than 2 nm are not suitable for medical use, as they diffuse 
through cell membranes, damaging intracellular organelles and thus exhibiting potentially toxic 
effects. Controlling the size of SPIONs during manufacturing is an important consideration for 
use in biomedical application. The techniques most employed for measuring the particle size 
of SPIONs are transmission electron microscopy and dynamic light scattering [23, 24].  
1.2.3 Drug loading 
Drug loading can be achieved either by conjugating the therapeutic molecules on the surface of 
SPIONs or by co-encapsulating drug molecules along with magnetic particles within the 
coating. The primary requirement, despite the loading method is that the active drug’s 
functionality is not compromised. Furthermore, the drug-loaded nanoparticles should also 
release the drug at the appropriate site and at a desired rate. Several approaches have been 
developed for conjugation of therapeutic agents or targeting ligands on the surface of these 
nanoparticles and they can be grouped under two categories: firstly, conjugation by means of 
cleavable covalent linkages onto the surface of polymer-coated SPIONs and secondly, by 
means of physical interactions [25] such as electrostatic, hydrophobic/hydrophilic and affinity 
interactions. 
1.2.4 SPION targeting approaches 
SPIONs can be properly engineered to reach their target tissue with minimum nonspecific 
cellular interactions. Targeting strategies can be grouped into three classes: passive, active and 
magnetic.  
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1.2.4.1 Passive targeting 
Passive targeting, as described before, takes advantage of the innate size of the nanoparticles 
as well as the unique characteristics provided by the tumour microenvironment [26]. Tumour 
cells exhibit leaky vasculature due to incomplete angiogenesis compared to healthy cells. This 
is also known as the enhanced permeability and retention effect [14, 15]. 
1.2.4.2 Active targeting 
Active targeting involves targeting ligands which are coupled at the surface of magnetic 
nanoparticles to interact with receptors that are overexpressed at their target sites. Such particles 
accumulate in larger quantities in target cells due to an attraction of these ligands onto the 
receptors and subsequent improvement of internalisation into cells. Various active targeting 
agents engineered and attached to the SPION surface not only ensure specific target binding 
but also minimize the dose required and nonspecific cellular interactions [9, 26, 27].  
1.2.4.3 Magnetic targeting 
Magnetic focusing uses external magnets to create a suitable magnetic field gradient over the 
targeted area and ensure significant accumulation of drug-loaded SPIONs [28]. The strength of 
the applied magnetic field can be altered to modulate release of the drug in the desired fashion, 
resulting in maximum therapeutic benefits [29]. Accumulation of SPIONs within malignant 
cells was found to be dependent on duration of exposure to the external magnetic field [30].  
1.2.5 Pharmacokinetics 
For SPIONs to be considered an effective modulation to biomedical treatments, it must have 
appropriate pharmacokinetic properties. Especially, their absorption into various cells, 
biodistribution and excretion from the body. 
1.2.5.1 Cellular uptake and biodistribution 
Literature reports several processes for cellular uptake of SPIONs. When administered 
intravenously, the SPIONs are predominantly taken up by phagocytes in the reticuloendothelial 
systems of the liver, spleen, and lymph tissue [31]. The SPIONs must cross the vascular 
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endothelium, in order to reach their target site(s) [32]. Particle size, surface coating, and surface 
charge are major determinants of the biodistribution, pharmacokinetics, and possible toxicity 
of SPIONs [22]. Tissue distribution is mainly affected by particle size. SPIONs with a particle 
size smaller than 50 nm evade opsonisation, thus increasing their circulation time and hence 
are gradually taken up by macrophages in the reticuloendothelial system (predominantly within 
the liver). In addition to particle size, the coating material used on iron oxide particles also 
determines the rate of hepatic clearance. In general, SPIONs covered with coating materials 
which hinder access of water to the iron oxide core show slower degradation and hence an 
increased half-life in blood [9, 12]. Surface charge, in addition to particle size and the coating 
material, affects the uptake of SPIONs by different cells. For example, positively charged 
SPIONs adhere nonspecifically to cells because the majority of the cell membranes have a net 
negative charge, whereas strong negative charges on the surface of magnetic particles facilitate 
their uptake by the liver [13, 19, 27, 33].  
1.2.5.2 Metabolism and excretion from biological systems 
An ideal drug delivery system, after delivering its payload to the target site, should be 
eliminated from the biological system with minimal harmful systemic effects. The uptake, 
distribution, metabolism, and excretion of dietary iron is highly regulated in biological systems. 
Specialized mechanisms which govern the body’s iron regulation processes are also thought to 
be involved in handling iron oxide nanoparticles. There remain only few reports in the literature 
clarifying their biotransformation in biological systems. Once internalised, lysosome-mediated 
degradation is generally considered to be the main intracellular metabolic mechanism involved 
in the degradation of SPIONs [34] [35, 36]. The most desirable pathway for SPIONs to be 
excreted from biological systems is via the kidney, because this route involves minimal 
intracellular catabolism, reducing the probability of generating reactive oxygen species and 
hence associated toxicity. Renal excretion represents the safest route of elimination for 
SPIONs. However, the shape, hydrodynamic size, surface coating, and surface charge of 
SPIONs play a major role in regulating their renal clearance [19, 29].  
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1.2.6 Utility as drug delivery vehicles 
SPIONs have emerged as an attractive prospect for targeted delivery of drugs because of their 
unique magnetic qualities. Their role as contrast agents in MRI has already been established 
[19] and increasingly are being investigated for their potential application in the delivery of 
chemotherapeutic drugs, radionuclides, and anti-inflammatory agents, as well as in gene 
delivery [7, 9, 25]. Magnetic fluid hyperthermia is another approach where SPIONs can be 
utilised for localized production of heat, resulting in destruction of cancer cells [37].  
1.2.6.1 Diagnostic use 
The only clinical use for which commercial SPION-based products are available is as MRI 
contrast agents for the diagnosis of human disease. SPIONs have been used as contrast agents 
for at least 20 years and have emerged as an suitable alternative to gadolinium-based MRI 
contrast agents, particularly in patients with renal dysfunction [19]. As this report is focused on 
the therapeutic usage of SPIONs, diagnostic applications are not discussed in detail. 
1.2.7 Role in cancer therapy 
Chemotherapeutic agents are well known to exert a multitude of unwanted systemic side effects 
due to their lack of target specificity. SPIONs can deliver chemotherapy drugs into malignant 
cells while sparing healthy cells. This also leads to reduction of the dose required because the 
drug is delivered directly to target cells. A number of anticancer drugs, including paclitaxel, 
methotrexate, mitoxantrone, and doxorubicin, have been conjugated with magnetic 
nanoparticles to increase their target specificity [9, 29, 38]. Further strategies can be utilised to 
increase the specificity of targeting cancer cells. These include, coating of SPIONs with 
polymers have resulted in increased interaction of these particular nanoparticles with human 
cancer cells, as well as reduced cytotoxicity in healthy cells [25, 39]. Cole et al. have shown 
polyethylene glycol (PEG)-modified, cross-linked, and starch-coated iron oxide nanoparticles 
have been found to enhance magnetic tumour targeting [40]. 
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1.2.8 Potential for theranostics 
Theranostics is a new field of medicine which combines specific targeted therapy based on 
specific targeted diagnostic tests providing a personalised and precision medicine approach. 
The theranostics paradigm involves using nanotechnology to unite diagnostic and therapeutic 
applications to form a single agent, allowing for diagnosis, drug delivery and treatment 
response monitoring. This is a particularly exciting prospect of SPIONs. As increasingly 
sophisticated multifunctional SPIONs are developed, as does the potential uses. Such 
nanocomplexes, can not only serve the purpose of being drug delivery vectors, but also have 
applications in another diagnostic or therapeutic aspect. Such examples include additional uses 
in MRI imaging [41] targeted thermosensitive chemotherapy [42], magnetically targeted 
photodynamic therapy [43], and fluorescence imaging [44]. 
1.2.9 Thermal ablation 
A drug-free approach to combating malignant cells involves localised heating of these cells 
from the inside. Cells begin to show signs of apoptosis when their inside temperature is raised 
in the range of 41–47°C. Necrosis results when the temperature reaches approximately 50°C. 
Targeted hyperthermia involves administration of magnetic nanoparticles, such as SPIONs, 
which are taken up by cells through endocytotic pathways and become concentrated in 
intracellular endosomal vesicles. When subjected to a high frequency AC magnetic field, these 
particles become heated because of Neel or Brownian relaxation losses in single-domain 
particles, resulting in localised cellular destruction [45]. The main drawback of this approach 
is ensuring the selective delivery of these nanoparticles to the desired cells to be target and the 
nanoparticles’ optimisation of their thermal properties to produce an effective magnetic 
hyperthermic effect. Coating tends to decrease heating efficiency, hence should be kept to a 
minimum [46]. 
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Figure 1: Common oncological applications for SPIONs [adapted (Palanisamy and Wang 2019)] 
1.2.10 Potential disadvantages of using SPIONs as drug vectors 
There several disadvantages with the use of SPIONs as drug delivery vehicles, which are briefly 
discussed below. 
1.2.10.1 Creating a suitable magnetic field gradient 
For successful implementation for SPION-based therapy is the development and maintenance 
of a suitable magnetic field to ensure effective localisation of the particles within the targeted 
cells and tissues; and furthermore, their successful internalisation with the desired cells. Blood 
circulation naturally offers resistance to a magnetic field developing [12]. Blood vessels and 
organs deep within the body cannot be targeted by external magnets because as the distance 
between the magnet and targeted area increases, the strength of the magnetic field at the desired 
site decreases. Only those areas which are close to the surface can be properly targeted using 
an external magnet. To overcome this limitation, research groups have been adopting 
superconducting magnets, which can exert strong magnetic fields. These magnetic fields have 
been found to penetrate the skin surface to a depth of 20 mm [47]. Magnetic stents or implants, 
which can create strong local magnetic fields, have also been used to increase the concentration 
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of drug-loaded magnetic nanoparticles at the desired site [48], however, an invasive surgical 
procedure is required and carries a morbidity risk [49].  
1.2.10.2 Burst effect 
Ideally, SPIONs should release their entire payload of the cytotoxic agent at the site of action, 
however, one limitation is the burst release of drug bound at the surface of the SPION. Any 
defective surface engineering leads to a premature release of a significant proportion of the 
drug load, which can lead to unnecessary systemic toxicity, that is, non-targeted release into 
the blood circulation. Certain strategies have shown to reduce the so-called burst effect, such 
as the use of crosslinked polymer coating [50] or utilising a starch coating [51]. 
1.2.10.3 Low bioavailability 
Intravenous administration is the route of choice for SPIONs, currently, commercially available 
SPION-based MRI contrast agents are generally given by the intravenous route. Although 
intravenous administration of these iron oxide nanoparticles ensures 100% systemic 
bioavailability, their specific uptake by target cells is an issue of concern because of nonspecific 
uptake by the reticuloendothelial system and non-specific binding to plasma proteins. However, 
with adequate surface engineering and the attachment of suitable targeting ligands, along with 
magnetic focussing, it is possible to enhance the uptake of drug-loaded SPIONs by target tissue, 
as previously discussed [7, 9, 11, 49, 52]. 
1.2.10.4 Toxicity  
Obviously, as SPION-driven drug delivery systems are relatively novel, despite showing 
promise, scrutiny is placed on pharmacokinetic and toxicity profiles. SPIONs are known to be 
excreted via endogenous metabolic iron pathways to maintain homeostasis [53]. Liu et al has 
performed significant research to demonstrate a low hazard potential for SPIONs with no 
murine deaths or transient adverse clinical signs [54]with no histological iron-positive pigments 
in macrophages of major organs, such as the liver, lungs, spleen, brain, kidney and heart [54]. 
A few reports have suggested some toxicological effects for SPIONs. Iron overload at the target 
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site is one of the causes of SPION-associated toxicity. After digestion of the coating, high levels 
of bare iron oxide nanoparticles at the target site can cause an imbalance in homeostasis. This 
can alter local cellular responses, leading to effects such as: DNA damage, inflammatory 
response, oxidative stress, genetic changes, disruption of cytoskeletal organization of cells, and 
unwanted cytotoxicity [12, 52]. After cellular uptake of SPIONs, they can be digested by 
lysosomes, resulting in release of free iron. These free iron ions (Fe2+) can react with hydrogen 
peroxide or oxygen in the mitochondria to form reactive free radicals which can cause cellular 
and genetic toxicity [39, 55]. Strategies to reduce this unwanted effect is to coat the SPIONs, 
commonly used are crosslinked polymers and dextran or starch. 
1.2.11 Summary and future direction for SPIONs in cancer therapy 
There are several novel and progressive drug delivery systems, including SPIONs. However, 
there are numerous factors that make SPIONs an extremely promising prospect as a drug 
delivery vehicle. There are relatively simple to assemble and have shown a low toxicity profile 
to date. They can be multifunctional in nature and can be specific manufactured to a high degree 
to target a specific cell type. Furthermore, their unique magnetic qualities enable another 
targeting mechanism, using an external magnetic field, which other nanomaterials do not 
possess. Carcinomas near the body surface, like squamous cell carcinoma, malignant 
melanoma, Kaposi’s sarcoma, and breast carcinoma, are likely to benefit the most from SPION-
based therapy because magnetic targeting works best in these regions [12]. They have shown 
potential applications in a wide variety of biomedical fields, both diagnostic and therapeutic. 
Disappointingly, despite decades of research and the outlined advantages there remains no 
SPION-based drug delivery product on the market. There are limitations which must be 
overcome to successfully launch a commercially available SPION-based product in the clinic. 
With the discovery of supermagnets, it has become possible to create a suitable magnetic field 
gradient deep inside the skin surface, which can lead to increased targeting capability of 
SPIONs. Further research is required especially towards the pharmacokinetics biodistribution 
and toxicity of SPIONs in vivo. Nevertheless, there is a remarkable rate of studies and research 
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involving SPIONs, that it is only a matter of time before SPION-based drug treatments are 
available in the clinic. 
 
1.3 Functionalisation of nanoparticles using antibodies 
1.3.1 Antibody structure and function and Specificity 
Antibodies are found in the serum and other bodily fluids of vertebrates that react specifically 
with antigens. Antibodies belong to the immunoglobulin family; and the term antibody and 
immunoglobulin can be used interchangeably. Immunoglobulins are defined as a family of 
globular proteins that comprise antibody molecules and molecules having patterns of molecular 
structure (antigenic determinants) in common with antibodies. The term immunoglobulin can 
be used to refer to any antibody-like molecule, regardless of its antigen-binding specificity [56]. 
However, this text will only deal with the IgG molecule. The primary function of an antibody 
is to bind to a foreign molecule (antigen). In humans, there is a vast array of antibodies due to 
millions of different amino acid sequence combinations. However, the antibodies remain 
structurally similar (grossly Y-shaped molecules). Antibodies are the most diverse proteins 
known. Due to the differing amino acid sequences in the arms of various antibody molecules, 
each different antibody can bind specifically one unique epitope. Thus, the arms of an antibody 
molecule confer the versatility and specificity of responses that a host can mount against 
antigens. The stem region of an antibody molecule decides its biological activity and defines 
whether the response against a particular antigen will lead to complement-mediated lysis, 
enhanced phagocytosis, or (in some cases) allergy [56]. These activities start once antibodies 
bind to antigen. The structure of an antibody is related to its function; its structure explains the 
binding versatility, binding specificity and biological activity. Pioneering experiments 
performed by Porter and Edelman [57, 58] discovered the finer structure of antibodies. Their 
research led to the 1972 Nobel in Medicine or Physiology. Whilst fragmenting the whole 
antibody molecule, Edelman discovered two subunits in equimolar ratios. He designated the 
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larger subunit (50 kiloDalton [kD]) as the heavy, or H, chain and the smaller subunit (23 kD) 
as the light, or L, chain; with the molecular weight of the original IgG molecule is 150 kD.  
1.3.2 Antibody specificity 
The antibody structure is further elaborated by the discovery of each chain consisting of a large 
region that was constant in different types of antibodies (even from unrelated species) and a 
similar-sized region that was highly variable. This large region, known as the constant (C) 
region, has amino acid sequences in the carboxyl terminal end of the chains that are almost 
identical; whereas the opposite end (amino terminal end) shows great variability in amino acid 
sequencing, called the variable (V) region [56]. This finding applies to both the light and heavy 
chains, leaving four distinguishable domains: variable light (VL), variable heavy (VH), 
constant heavy (CH1-3) and constant light (CL). As amino acid sequencing determines the 3D 
structuring of proteins, the unique sequence of each variable region leads to the large diversity 
of structure, which accounts for antibody specificity. Variability of the amino acid sequences 
in the V regions is not random but precisely organised. 
 
 
Figure 2: showing the various sites of an antibody. Two light chains and two heavy chains. The antibody has 
an amine terminal (N) and carboxyl terminal (C). The darker areas represent the constant regions and the 
lighter areas the variable regions (Bio-Rad 2014). 
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1.3.3 Conjugation of antibodies to nanoparticles 
The conjugation of different moieties to the nanoparticle widens their application and provides 
them with new or enhanced properties. A variety of ligands have been explored for such 
purposes, including aptamers, peptides and carbohydrates, although antibodies are perhaps the 
most frequently employed [59, 60].  The conjugation of nanoparticles with antibodies combines 
the properties of the nanoparticles themselves with the specific and selective recognition ability 
of the antibodies to antigens [61]. This is to improve the targeting specify of the nanoparticle 
to its desired cell. This is one method of active targeting of nanoparticles. Furthermore, the 
chemistry applications in order to conjugate antibody attachments onto nanoparticles is not 
discussed in this text. 
 
1.4 Pancreatic Cancer 
1.4.1 Overview 
Pancreatic cancer is the 11th most common cancer worldwide and, in the UK, with around 
338,000 new global cases annually and around 10,000 cases in the UK between 2014-16. There 
are around 9,200 pancreatic cancer deaths in the UK every year, and is the 5th most common 
cause of cancer death in the UK, accounting for 6% of all cancer deaths in 2017 [5]. Since the 
early 1970s, pancreatic cancer mortality rates have remained stable in the UK. Over the last 
decade, pancreatic cancer mortality rates have increased by 5% in the UK [5]. The causes for 
pancreatic cancer remain unknown. Several environmental factors have implicated, but tobacco 
use is the only causative factor with evidence: the risk of developing pancreatic cancer is 2.5 to 
3.6 times higher in smokers, where the risk increases with greater tobacco use and longer 
exposure [62]. Some studies have shown an increased incidence of pancreatic cancer among 
patients with diabetes mellitus or chronic pancreatitis and data is limited for on the possible 
roles of alcohol, coffee consumption and aspirin use [63-65]. 
Sumit Nandi  Treatment of pancreatic cancer using gemcitabine-loaded SPIONs 
 30 
1.4.2 Poor prognosis 
Pancreatic ductal adenocarcinoma (PDAC) is considered as the most common pathological type 
of pancreatic cancer and contributes to 94% of pancreatic cancers [66]. PDAC remains difficult 
to diagnose, as symptoms are often vague and only later when recognisable symptoms, such as 
jaundice, weight loss and abdominal pain arise. Unfortunately, by the time of diagnosis, many 
patients experience either a locally advanced stage or distant metastasis, and then become 
ineligible candidates for major potentially curable surgery. The current terrible outcomes for 
patients with pancreatic cancer can in part attributed to: the difficulty in obtaining an early 
diagnosis; the inability to detect pre-cancerous lesions (pancreatic intraductal neoplasms) and 
the lack of any reliable serum biomarker(s) with accuracy to detect early either pre-malignant 
lesions [67] or a developing invasive malignancy. Consensus shows that patients with 
pancreatic cancer were often observed with 90% KRAS mutations, 50 to 80% inactivating 
mutations in CDKN2A, SMAD4, and TP53 [68]. 
 
All of this summates into only 20% of patients at the time of diagnosis are suitable for 
potentially curative resection. Without treatment, survival is approximately 18% at one year 
and 3.7% at five years [69]. Only 1% of people diagnosed with pancreatic cancer in England 
and Wales survive their disease for ten years or more (2010-11) [5]. The five-year relative 
survival rates for pancreatic cancer are the lowest of the 21 most common cancers in England 
[70]. At present the only chance for long-term survival (29% 5-year survival) is with a 
combination of curative surgery and adjuvant therapy, however, recurrence occurs in 55% of 
patients at 2 years and 70% at 5 years [71, 72].  
 
These dismal statistics indicate that is an urgent need to ensure better diagnosis and treatment 
for PDAC to improve any survival benefit. Novel approaches, such as the use of 
nanotechnology applications may be a potential theranostic solution. 
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1.4.3 Molecular biology of pancreatic ductal adenocarcinoma 
PDACs are complex, with the tumoural mass comprising a multitude of different cell types. Its 
surrounding desmoplastic environment (also known as stroma) is a hallmark of the disease. 
Stroma contains a number of cellular components including cancer-associated fibroblasts 
(CAFs), macrophages, lymphocytes and pancreatic stellate cells (PSCs), embedded within a 
dense and complex extracellular matrix (ECM) [73]. PDAC has the unique property of a high 
ratio of stroma to epithelial cells, with stroma commonly accounting for more than 90% of the 
tumour volume [74]. 
1.4.4 Role of stroma 
The role of stroma in PDAC is currently under intense scrutiny. It is widely accepted to promote 
and facilitate tumour cell proliferation, migration, and invasion [75-77]. However, further 
research is on-going and is needed to fully comprehend its function [78]. PSCs, which comprise 
approximately 4% of the cells in the pancreas [79], are the principle cell type responsible for 
the production of stromal fibrosis. The high proportion of stromal cells causes overexpression 
of several growth factors and their associated receptors, such as vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF), connective tissue growth factor (CTGF) and 
fibroblast growth factor (FGF). It is these growth factors that have an intricate relationship with 
the stroma and tumour itself and further modulates the tumour’s behaviour. It is apparent that 
tumour cell-autonomous changes alone are not enough for tumour growth. Tumour cell-
extrinsic factors are prominent in the pathogenesis of PDAC [80]. 
1.4.5 Chemotherapy resistance 
The stroma of pancreatic cancer is extensively fibrotic which results in a reduced intra-tumoural 
vascular density, which in turn causes damaged/collapsed vessels (up to ~75%)  and reduced 
blood flow; poor venous and lymphatic drainage; and increases the tumour’s interstitial 
pressure [81, 82]. This is a contradistinction to most solid tumours and indeed, perfusion 
Computer Tomography (CT) scans show PDAC as hypodense regions i.e. areas that uptake less 
injected contrast material than surround normal tissue [83]. Chemotherapy drug delivery to 
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pancreatic tumour is difficult due to its hypo-vascularity and poor perfusion, furthermore, the 
dense stroma prevents drugs from penetrating the tissue’s interstitium [84-86]. The difficulty 
in infiltrating the PDAC tumour load, can be exploited by nanotechnology, namely 
nanoparticles, due to their size predominantly, but also with the addition of an active targeting 
method e.g. ligand for a specific tumour epitope. In addition, the abundance of 
immunosuppressive cells leads to low numbers of effector CD8+ T cells in the stroma and 
consequently limited anti-tumour cytotoxicity [87]. 
1.4.6 Potential targets for Drug Discovery  
The unique microenvironment in PDAC has been shown to play a major role in tumour growth 
and chemotherapy resistance. Therefore, the elimination of stromal support by destroying the 
stromal cells or by inhibiting feedback stimulation of cancer growth is in the focus of many 
evolving therapies, the concept of “anti-stromal” therapy [88]. Given the tumour mass comprise 
mainly of the fibrotic stroma, the extracellular matrix components or PSCs residing within the 
stroma could be novel targets for early diagnosis, imaging and targeted therapy [89] as they can 
affect the biology of the tumour cells and form barriers to drug delivery. Consequently, these 
stromal targets could be important as starting points for the drug discovery process (target 
identification and subsequent validation). A selection of the most promising stromal 
components for drug discovery targeting are summarised in Table 2. 
1.4.7 Carbohydrate antigen 19-9  
Although both benign and malignant pancreato-biliary tissue produce biomarkers, they are of 
particular interest in cancer management. Early in the formation of a cancer, they are present 
in the circulation at usually very low or undetectable levels [7, 90].  The Sialyl Lewis A antigen, 
or carbohydrate antigen 19-9 (CA 19-9) is the most commonly used biomarker for diagnosis 
and management of patients with pancreatic cancer. Since the original research by Steinberg in 
1990, numerous studies have reported the use of CA 19-9 in the diagnosis of pancreatic cancer 
[91, 92] and at present, serum CA 19-9 is the only validated tumour marker in widespread 
clinical use. Several immunochemical markers have been proposed for pancreatic cancer such 
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as carcinoembryonic antigen (CEA), MUC3, MUC4, MUC1, and CA125, but currently the only 
one with any practical usefulness is CA 19-9 [93, 94], although not suitable for screening. The 
reported sensitivity and specificity of CA 19-9 for pancreatic cancer is between 80 to 90 percent 
[91, 95, 96]. Serum level of this marker rises in benign pancreatobilliary disease, so its 
specificity for adenocarcinoma is limited.. Nevertheless, the use of CA 19-9 for the 
differentiation of pancreatic cancer should be applied on an individual case basis, depending 
on the clinical situation and imaging findings and remains an important adjunct. 
1.4.8 Potential uses of nanotechnology against micro-environment targets 
Without doubt, understanding of the complex stromal constituents and involvement of 
numerous signalling pathways in pancreatic cancer progression and desmoplastic reaction is 
crucial to the development of novel therapies through the drug discovery process. As an 
increasing number of targets are explored with improved knowledge of the tumour 
microenvironment, the application of nanotechnology has a huge role to play in validating those 
targets. Given the vast array of targets available, nanotechnology would allow faster and more 
reliable extraction of protein targets from samples using proteomic techniques described above. 
Furthermore, the stromal-tumour interactions may well be directly visualised with the aid of 
nanoscale imaging, such as fluorescence studies (through quantum dots) and atomic force 
microscopy. Finally, if encouraging targets are identified, nanomaterials themselves may be 
used as therapeutic carriers against the target of interest. 
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Table 2: Table summarising the stromal components that could be potential drug discovery targets. (IL-10: interleukin-10; Th2: T-helper 2 cells; TGFβ: transformation growth factor 
β)  
Component Effect on tumour Mechanism Potential for therapy 
Fibroblasts 
Pancreatic 
stellate cells 
(PSCs)  
Promote proliferation and 
invasion 
Expression of  fibroblast 
activation protein-α (FAP) 
[97] 
• Depletion of FAP-expressing stromal cells in pancreatic ductal adenocarcinoma (PDAC) resulted in an 
immune-mediated hypoxic necrosis of both tumour and stroma cells [98].  
• Targeting of cancer stroma fibroblasts with FAP-activated promelittin protoxin, showed increased tumour 
lysis and growth inhibition in xenograft mouse models of breast and prostate cancer [99]. 
• However, anti-FAP antibodies tested in phase II clinical trials in patients with metastatic colorectal cancer 
did not report encouraging results [100].  
Creates fibrotic environment 
leading to increased 
chemotherapy resistance 
Increases secretion of 
collagen I, III, IV; 
fibronectin, laminin, 
hydraluronan and growth 
factors [101] 
ECM 
Collagen I Activates pancreatic stellate cells Increased expression of 
transgelin, increasing 
desmoplastic reaction and 
fibrosis [102] 
• Mouse models have shown degradation of hyaluronan (with hyaluronidase) relieved vascular collapse 
and resulted in increased cytotoxicity of gemcitabine [103].  
• Subsequent development of PEGPH20 (pegylated recombinant human hyaluronidase) showed partial 
response in 43% of patients and stable disease in additional 30% patients in phase Ib clinical trials in 
patients with metastatic disease [104]. 
• A randomized phase II clinical trial of PEGPH20 in combination with gemcitabine and nab-paclitaxel is 
in progress (NCT01839487) [105] . 
Hydraluronan Increases intra-tumoural fluid 
pressure and consequent vascular 
collapse  
Causes water retention 
[106] 
(Tumour-infiltrating) Immune Cells 
Myeloid-derived 
suppressive cells 
(MDSCs) 
Implicated in tumour progression, 
chemotherapy resistance and 
metastasis and regulates effector 
cells anti-tumour responses by 
variety of mechanisms [107, 108] 
Inhibit CD8+ T cell 
function via arginase, and 
reactive oxygen species 
secretion (direct cell 
contact) [109] 
Targeted depletion of granulocytic MDSCs in PDAC significantly increased intratumoural accumulation of 
activated CD8+ T cells and apoptosis of tumour epithelial cells in vitro and in genetically engineered mouse 
models. [110] 
T-regulatory 
cells 
Secretion of suppressive 
cytokines e.g. IL-10 and 
TGFβ [111] 
Targeting of downstream targets such as TGFβ. 
Tumour 
associated 
macrophages 
M1 (pro-inflammatory) and  
M2 (immunosuppressive) 
Source of anti-
inflammatory cytokines 
such as IL-10 and have 
been shown to induce Th2 
responses [112] 
Tumour regression seen due to depletion in tumour associated macrophages  in clinical study combining CD40 
antibody with gemcitabine in advanced disease [113].  
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1.5 Gemcitabine 
Gemcitabine (2’,2’-difluoro 2’-deoxycytidine, dFdC) is an analogue of cytosine arabinoside (Ara-C) 
from which it differs structurally due to its fluorine substituents on position 2’of the furanose ring. 
[114]. Gemcitabine is a prodrug which requires cellular uptake, where it is phosphorylated to 
gemcitabine monophosphate (dFdCMP) by deoxycytidine kinase (dCK). It is subsequently to its active 
metabolites, gemcitabine di- and triphosphate respectively [114]. 
 
 
Figure 3: chemical structure of gemcitabine 
1.5.1 Intra-cellular actions 
Gemcitabine, through its active metabolites has many potential intra-cellular targets to prevent cell 
growth, mainly targeting DNA synthesis [114]. Gemcitabine triphosphate (dFdCTP) is an inhibitor of 
DNA polymerase and its incorporation into the DNA chain leads to termination of chain elongation. 
[115, 116], the non-terminal position of dFdCTP in the DNA chain prevents detection and repair by 
DNA repair enzymes (masked chain termination) [117, 118]. Furthermore, dFdCTP is known to 
incorporate into RNA. These molecular events are critical to gemcitabine-induced apoptosis. 
1.5.2 Uses in cancer therapy 
Gemcitabine displays a wide spectrum of anti-tumour activity. In the UK, the National Institute for 
Health and Care Excellence (NICE) is currently approved for first-line treatment for locally advanced 
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or metastatic non-small cell lung cancer (as monotherapy in elderly patients and in palliative treatment; 
otherwise in combination with cisplatin),  treatment of locally advanced or metastatic pancreatic cancer, 
treatment of advanced or metastatic bladder cancer (in combination with cisplatin), treatment of locally 
advanced or metastatic epithelial ovarian cancer which has relapsed after a recurrence-free interval of 
at least 6 months following previous platinum-based therapy (in combination with carboplatin) and 
treatment of metastatic breast cancer which has relapsed after previous chemotherapy including an 
anthracycline (in combination with paclitaxel) [119].  
1.5.3 Uses in pancreatic cancer 
Despite previously being licensed as a single agent for adjuvant therapy for all stages of pancreatic 
cancer, gemcitabine has been superseded by combination therapies. For resectable disease, adjuvant 
therapies now involve combination strategies (with capecitabine), demonstrating a 2.5 month 
improvement in overall survival compared with gemcitabine alone [120]. After being approved by US 
FDA in 1997, gemcitabine was the first line and gold standard agent for all stages of advanced PDAC. 
However, combination regimens such as, FOLFURINOX (includes the drugs leucovorin calcium, 
fluorouracil, irinotecan hydrochloride, and oxaliplatin) or gemcitabine combination therapies are the 
current first-line option for resectable disease.  
 
At the time of this research, gemcitabine was considered the ‘gold standard’ of treatment against 
pancreatic cancer and was in use at all stages of the disease. However, as described, more sophisticated 
oncological regimens have grossly diminished its use, becoming somewhat of a second-line treatment 
and reserved for advanced stages of the disease.  
1.5.4 Limitations of gemcitabine 
Gemcitabine has been surpassed as the cornerstone of PDAC treatment for a variety of reasons. The 
major drawbacks are effects primarily caused by molecular mechanisms limiting its cellular uptake and 
activation which determines its overall efficacy. There is low bioavailability after its administration, 
due to rapid inactivation by blood deaminases, resulting in a very short plasma half-life. Furthermore, 
there is a described development of chemoresistance within weeks of treatment initiation. According to 
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the U.S Food & Drug Administration (FDA), gemcitabine half-life for short infusions ranged from 
32 to 94 minutes, and this increased to 245 to 638 minutes with longer infusions. The values 
were dependent on depending on age and gender [121]. The main cause for the fast development 
of cell chemoresistance is induced by down-regulation of deoxycytidine kinase (dCK) or nucleoside 
transporters [122], predominantly human equilibrative nucleoside transporter-1 (hENT1). Thus, a 
frequent administration schedule at high doses is required, leading to significant side effects such as 
hepatotoxicity and nephrotoxicity [123]. The majority of patients with gemcitabine-treated pancreatic 
adenocarcinoma become resistant after consecutive treatments and fail to derive benefit from 
chemotherapy. 
1.5.5 Gemcitabine resistance 
Gemcitabine has a complex pathway of metabolism, and there are many mechanisms that can contribute 
to gemcitabine cytotoxicity and conversely its resistance [124]. Studies performed on human cancer 
cell lines have indicated that human equilibrative nucleoside transporter-1 (hENT1) was found to be 
gemcitabine’s dominant cellular transporter [125], which is over-expressed in human pancreatic 
adenocarcinoma cells. If gemcitabine is not transported into the cell via hENT1 it cannot inhibit cell 
growth [126, 127]and studies have shown that a decrease in hENT1 expression may result in 
gemcitabine resistance in PDAC [128, 129]. Increased hENT1 abundance facilitates efficient cellular 
entry of gemcitabine and confers increased cytotoxicity [130, 131]. Once intra-cellular, gemcitabine is 
phosphorylated by deoxycytidine kinase in a rate-limiting step. And its deficiency is acknowledged to 
be one of the main mechanisms responsible for the development of resistance to gemcitabine.  
 
 
To counteract gemcitabine’s poor bioavailability and chemoresistance in PDAC, several novel 
therapeutic approaches, including chemical modifications of the gemcitabine molecule generating 
numerous prodrugs, not rendering it dependent on the nucleoside transporter and/or entrapping 
gemcitabine designs in colloidal systems such as nanoparticles and liposomes may be a successful 
future more targeted mode of chemotherapy treatment.  
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1.6 Chemotherapy treatments in pancreatic cancer 
The chemotherapy regimens offered to patients is dependent on the stage of the disease, broadly 
speaking, if the cancer is surgically amenable to resection or not; either due to locally advance disease 
or metastases. The disease status governs which agents are considered. 
1.6.1 Current chemotherapy treatments for pancreatic cancer 
Table 3 below summarises the current chemotherapy strategies that are recommended in the UK as per 
the most recent NICE guidance from 2018. 
Resectable or borderline resectable disease 
Neoadjuvant therapy Surgery Adjuvant therapy 
Only considered as part of a 
clinical trial. 
Consider pylorus-preserving 
resection (for head of pancreas 
tumours) if can be adequately 
resected with standard 
lymphadenectomy. 
Offer adjuvant gemcitabine plus 
capecitabine to people as soon as they 
are well enough to tolerate all 6 cycles. 
Consider adjuvant gemcitabine for 
people who are not well enough to 
tolerate combination chemotherapy. 
Locally advanced disease 
Offer systemic combination chemotherapy to people with locally advanced pancreatic cancer who are well 
enough to tolerate it or consider gemcitabine alone if unable to tolerate combination chemotherapy. 
Metastatic pancreatic cancer 
First-line treatment Second-line treatment 
• Offer FOLFIRINOX with performance status 
0-1. 
• Consider gemcitabine combination therapy 
(with nab–paclitaxel) for people who are not 
well enough to tolerate FOLFIRINOX. 
• Offer gemcitabine to people who are not well 
enough to tolerate combination chemotherapy. 
• Consider oxaliplatin-based chemotherapy, for 
those who have not received as first-line 
treatment. 
• Consider gemcitabine-based chemotherapy as 
second-line treatment for people whose cancer 
has progressed after first-line FOLFIRINOX. 
Table 3: Summary of current recommended chemotherapy agents and regimens as indicated by NICE in the UK. 
Adapted from [132] (FOLFURINOX: includes the drugs leucovorin calcium, fluorouracil, irinotecan hydrochloride, 
and oxaliplatin; nab-paclitaxel = nanoparticle albumin-bound paclitaxel) 
1.6.2 Nanoparticle albumin-bound (nab)-paclitaxel 
Nanoparticle albumin-bound (nab)-paclitaxel is paclitaxel linked to albumin nanoparticles which makes 
it soluble and is an example of application of nanotechnology to cancer treatment; and the only example 
concerning pancreatic cancer. Nab-paclitaxel (Abraxane®) is a microtubule inhibitor, it was developed 
to avoid the toxicities of the polyoxyethylated castor oil solvent which is used for unbound paclitaxel 
because of its poor aqueous solubility [133, 134]. The nanoparticle-driven delivery system has 
pharmacokinetics and pharmacodynamics of paclitaxel, in part by decreasing its hydrophobicity. The 
use of nab-paclitaxel, combined with gemcitabine, was founded on molecular profiling of malignant 
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pancreatic tumours, which identified overexpression of secreted protein acidic and rich in cysteine 
(SPARC), an albumin-binding protein [135]. Nab-paclitaxel is now used in the UK as first-line 
combination therapy with gemcitabine for metastatic adenocarcinoma of the pancreas (see table 3). 
 
1.7 Nanotechnology in pancreatic cancer 
Nanoparticles provide an attractive approach in the treatment of pancreatic cancer. As discussed, they 
can be modified to contain a  variety of therapeutic agents and also be conjugated to ligands to facilitate 
active targeting [136]. Furthermore, they confer an option to negotiate the hypo-vascular and densely 
fibrotic stroma, with which current chemotherapy options has had limited success. Pancreatic cancer 
expresses a number of potential targets that can be aimed for by conjugated nanoparticles, these include: 
antibodies (CA-19-9, Carcinoembryonic antigen [CEA], CA-125, bombesin, Epithelial cell adhesion 
molecule [EpCAM]) and receptor ligands (Urokinase receptor [uPAR], epidermal growth factor 
receptor [EGFR]) [15, 137]. PDAC has a rather unique micro-environment typified by a dense hypo-
cellular stroma, which contains important growth factors, pancreatic stellate cells, fibroblasts and 
lymphocytes. There is a complex interplay between these elements which promote fibrosis, invasion 
and migration of the cancer. Furthermore, this barrier is relatively avascular limiting the effects of drugs 
entering into the mass. Conversely the stroma has an abundance of potentially ‘drug-able’ targets and 
the extrapolations of nano-techniques to probe this are immense. Current examples being tested with 
stromal modulation followed by cytotoxic/immune based therapies are: PEGylated nanoparticles 
carrying TGF-β inhibitor and follow on liposomal gemcitabine [138]; and PEGylated human 
recombinant PH20 hyaluronidase [103]. Nanotechnology can facilitate with the identification and 
validation of targets; and furthermore, once suitable targets are selected can visualise drug interactions 
and test efficacy of the therapies. Drug discovery is constantly stimulated by new technologies and the 
rapidly advancing research field of nanotechnology provides a focus on developing novel therapy 
approaches for various diseases. These applications can have an impact in the discovery of therapies in 
pancreatic cancer, where new approaches are desperately required. Table 4 summarises promising 
research into the use of nanotechnology for the treatment of pancreatic cancer.  
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Table 4: Table outlining promising research into the use of nanotechnology for the treatment of pancreatic cancer. (uPAR: urokinase plasminogen activator receptor; MRI: magnetic 
resonance imaging; PEG: poly(ethylene glycol); TGF-β: transforming gene factor) 
Nanotechnology  Outcomes Reference 
Nab-paclitaxel or Abraxane® (Abraxis 
Bioscience): albumin-bound paclitaxel 
• Phase I/II trial for pancreatic cancer demonstrated the maximum-tolerated dose for 
Nab-paclitaxel in combination with gemcitabine.  
• Improved overall survival in patients treated with nab-paclitaxel plus gemcitabine 
(12.2 median months of overall survival) compared to gemcitabine alone.  
• Nab-paclitaxel alone and in combination with gemcitabine was shown to deplete 
pancreatic stroma in xenograft mouse models. 
• This led to a 2.8 fold increase in the intra-tumoural concentration of gemcitabine. 
[139] 
uPAR-targeted magnetic iron oxide 
nanoparticles IONPs carrying gemcitabine 
• Significantly inhibited the growth of orthotopic mice xenografts and allowed 
detection of residual tumours after treatment using MRI. 
[140] 
Polymeric micelles consisting of a 
oxaliplatin-loaded hydrophobic core and 
poly(ethylene glycol) hydrophilic shell. 
• Repeated systemic administration of the nanoparticles significantly reduced tumour 
growth and metastases in transgenic mouse model. 
[141] 
Nanoparticle encapsulated with pro-drug of 
gemcitabine [4-(N) stearoyl gemcitabine] 
 
• Overcome gemcitabine resistance associated with M1 cell overexpression in 
pancreatic cancer cells. 
[142] 
PEGylated human recombinant PH20 
hyaluronidase (PEGPH20) targeting 
hyaluronic acid 
 
• Systemic administration in a mouse model; produced marked decrease stroma and 
subsequent decrease in interstitial tumour pressure and [139] increased tumour 
blood vessel lumen diameter.  
• When delivered in combination with gemcitabine there was a strong chemotoxic 
effect compared to gemcitabine alone. 
[103].  
 
Polyethyleneimine / PEG-coated mesoporous 
silica nanoparticle for molecular 
complexation to a small molecule TGF-β 
inhibitor, LY364947 followed by PEGylated 
gemcitabine-carrying liposome  
• Two-wave nanotherapy approach improved the delivery of gemcitabine as the first-
wave nanocarrier reducing stromal resistance by decreasing pericyte coverage of the 
vasculature through interference in the pericyte recruiting TGF-β signaling 
pathway. 
• This two-wave approach provided effective shrinkage of the tumour xenografts 
beyond 25 days, compared to the treatment with free drug or gemcitabine-loaded 
liposomes only.  
[138] 
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1.8 Aims of the Study 
There were various aims from the research conducted. Firstly, it was to determine the effective 
cytotoxic effects of the gemcitabine within a novel nanoparticle drug carrier against pancreatic 
cancer cells in vitro. Secondly, was to determine any potential active targeting methods that 
could be utilised to increase the cytotoxic effects of the gemcitabine-loaded SPIONs. Finally, 
to determine whether the gemcitabine-loaded SPIONs would be successful in producing any 
cytotoxic effect whilst circulated within a flow model. 
 
1.9 Plan of the study 
• Consistent and reproducible manufacture and storage of gemcitabine-loaded SPIONs 
• Growth and maintenance of immortalised pancreatic cancer cell lines 
• Assessment of antigen expression of pancreatic cancer cell lines 
• Determine cytotoxicity of gemcitabine-loaded SPIONs against cancer cells 
• Potentiate any cytotoxicity using a specific targeting ligand: CA 19-9 antibody 
• Replicate any 2D results within a 3D culture set-up 
• Construct an artificial circulatory system to assess for improved cytotoxicity using 
magnetic targeting 
Sumit Nandi  Treatment of pancreatic cancer using gemcitabine-loaded SPIONs 
 42 
2 Material and Methods 
2.1 Manufacture of nanoparticles 
2.1.1 Multifunctional iron oxide nanoparticles 
The superparamagnetic iron oxide nanoparticles (SPIONs) used in my experiments have previously 
been described and optimised by the Rosseinsky Group at the Department of Chemistry, University of 
Liverpool in close collaboration with Prof. Christopher Halloran at the Department of Molecular and 
Clinical Cancer Medicine. They were initially used in vitro for biological applications by my colleague, 
Mr Paul Sykes. The production of these tailor-made nanoparticles is described in Olariu et al. [137]. 
2.1.2 Component parts of the nano-complexes 
The SPIONs used in the experiments are comprised of several individually tailored components which 
are combined to form the completed nano-complexes in a self-assembly methodology. Table 5 
summarises component parts of the self-assembled nano-complexes. 
Component Name Details 
Core Hydrophobically-modified 
superparamagnetic iron 
(II,III) oxide nanoparticles 
(SPIONs) 
Arranged in a central cluster 
Fluorescent tag Octadecyl rhodamine  Arranged in the mixed hydrophobic core 
Polymer Amphiphilic poly (2-ethyl)-2-
oxazoline 
Sterically stabilises the nano-complex.  The 
end-alkyl chain is arranged in the mixed 
hydrophobic core and the polymer segment 
organises as the outer hydrophilic shell 
Chemotherapy 
pro-drug 
Hydrophobically-modified 
pro-drug of gemcitabine  
Arranged in the mixed hydrophobic core of 
the nano-complex 
Targeting 
antibody 
Either isotype or specific 
antibodies were attached  
Covalently bonded onto the hydrophilic 
segment of the polymer shell 
Table 5: Component parts of the self-assembled nano-complexes used in experiments. 
2.1.3 Characterisation of the manufactured nano-complexes 
The nano-complexes manufactured were characterised to determine the average diameter, iron 
concentration of its core and drug (gemcitabine) concentration loaded. 
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2.1.3.1 Dynamic Light Scattering (DLS) 
The hydrodynamic diameters of SPION samples were measured using a Malvern Zetasizer Nano ZS 
equipped with a helium laser at a wavelength of 633 nm. 1mL sample was used for each measurement. 
Scattered light was collected at a fixed angle of 173⁰ and measurements were performed at 25 °C. The 
intensity-average hydrodynamic diameters reported are obtained from 3 independent measurements; 
for each measurement at least 20 repeat runs were used. 
This protocol is described in Olariu et al. [137] and were kindly performed by Dr Mike Barrow, 
Department of Chemistry, University of Liverpool. 
2.1.3.2 Zeta potential 
The zeta potential of the SPION samples dispersed in deionised water or buffers were measured using 
a Malvern Zetasizer Nano ZS equipped with a helium laser 633 nm wavelength. An aliquot of 1 mL 
sample was used for each the measurement. The measurements were performed at 25 °C. The zeta 
potential values reported are obtained from 3 independent measurements; for each measurement at least 
50 repeat runs were used. 
This protocol is described in Olariu et al. [137] and were kindly performed by Dr Mike Barrow, 
Department of Chemistry, University of Liverpool. 
2.1.3.3 High performance liquid chromatography  
This technique was used to determine the average concentration of iron and drug (gemcitabine) within 
each batch of SPION samples. The SPIONs that were manufactured for the use in my experiments had 
an iron core concentration of 1mM/mg and pro-drug gemcitabine concentration of 0.2mg/ml. 
2.1.3.4 Overview of nanoparticle manufacture 
In brief, independently synthesized hydrophobic SPIONs (Figure 4F) and amphiphilic poly (2-ethyl-2-
oxazoline) (PEtOX) (Figure 4A) were self-assembled together with a fluorescent dye (Octadecyl 
Rhodamine B) in a 10:1:0.01 mass ratio respectively to yield a multifunctional NP (Figure 4G). The 
PEtOX polymer via its hydrophobic segment, hydrophilic and carboxylic end functional groups can 
form important interactions with Rhodamine B, proteins, antibodies and gemcitabine. To manufacture 
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drug-loaded particles, gemcitabine was modified through conjugation of a hydrophobic alkyl chain with 
the gemcitabine molecule using a pH sensitive acetal bond (Figure 4B). This resulting amphiphilic 
compound was then added to the nanoparticle components in a ratio of 4:1 resulting in a self-assembled 
drug-laden nanoparticle.  
 
 
Figure 4: Composition of multifunctional SPION. A – Schematic of amphiphilic PEtOX, B – Modified Gemcitabine, C 
–Gemcitabine released from the acetal group and alkyl chain, D – Rhodamine fluorescent dye, E – Antibody, F – Oleic 
acid coated iron oxide cores conjugated with alkyl chains, G –  The assembled NP  (Illustration courtesy Dr E. Hasan, 
Department of Chemistry, University of Liverpool, UK) 
2.1.3.5 Laboratory manufacture of nanoparticle complexes 
I was kindly demonstrated the above chemistry protocol by Dr Erol Hasan, Department of Chemistry, 
University of Liverpool. I was able to manufacture nanoparticles in the tissue laboratory using the self-
assembly components. 4mg of pro-drug gemcitabine and 20mg of polymer was added to 2ml of 
Tetrahydrofuran (THF). 2µg of Rhodamine was added and thoroughly mixed. 20ml of distilled water 
(dH20) was added, and solution was placed in a 37oC water bath and ultrasonically mixed for 15 
minutes. This was then added to a dialysis tube and submerged into phosphate buffered saline [PBS], 
covered with aluminium foil and left in dialysis for 48 hours. The PBS was changed after 24 hours. The 
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SPION complexes used throughout the experiments were stable in distilled water or PBS and were 
effective for use for 3 months after production. 
 
2.2 Cell lines and culture 
2.2.1 Cell culture of primary immortalised cancer cell lines 
Several commercially available cell lines were used during my laboratory work. All cell lines were 
grown within media supplemented with additional supplements. Table 6 summarises the media, 
additional supplements and other reagents used during cell culture. These cell lines and their passaged 
clones were checked for genotyping to ensure no unwanted mutations and also for mycoplasma 
contamination. 
Supplement / Reagent Supplier 
RPMI-1640 Medium (with NaHCO3) Sigma-Aldrich Company Ltd, Dorset, UK 
Dulbecco’s Modified Eagle Medium (DMEM) 1x 
(high glucose with added sodium pyruvate) 
Gibco © Life Technologies Ltd, Paisley, UK 
Foetal bovine serum (FBS) – Origin: South 
America. 
Gibco © Life Technologies Ltd, Paisley, UK 
 
Penicillin-Streptomycin (10,000 units penicillin; 
10mg streptomycin per ml) 
Sigma-Aldrich Company Ltd, Dorset, UK 
L-Glutamine (200nM) Sigma-Aldrich Company Ltd, Dorset, UK 
Trypsin-EDTA solution Sigma-Aldrich Company Ltd, Dorset, UK 
HEPES (1M) buffer solution Gibco © Life Technologies Ltd, Paisley, UK 
2-Mercaptoethanol Sigma-Aldrich Company Ltd, Dorset, UK 
Phosphate-buffered saline (PBS) [pH 7.4, 1x] Gibco © Life Technologies Ltd, Paisley, UK 
Dimethyl Sulfoxide (DMSO) Fisher Scientific, Leicestershire, UK 
Table 6: Reagents and supplements used in cell culture 
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Table 7 summarises the cell lines used, their characteristics and the media they were kept in. 
Name Tissue 
Origin 
Disease Supplier Media CA 19-9 
expression 
BxPC-3 Pancreas Adenocarcinoma ATCC ® 
#CRL-1687  
RPMI + 10% FBS + 
1% L-Glut + 1% 
Pen-Strep 
Yes 
PANC-1 Pancreas/d
uct 
Epithelioid 
carcinoma  
ATCC ® 
#CRL-1469 
RPMI + 10% FBS + 
1% L-Glut + 1% 
Pen-Strep 
Yes 
CFPAC-1 Pancreas; 
derived 
from 
metastatic 
liver 
Ductal 
adenocarcinoma; 
cystic fibrosis 
ATCC ® 
#CRL-1918 
RPMI + 10% FBS + 
1% L-Glut + 1% 
Pen-Strep 
Yes 
SUIT-2 Pancreas Adenocarcinoma ATCC ® 
#CRL-1687 
RPMI + 10% FBS + 
1% L-Glut + 1% 
Pen-Strep 
Yes 
MIA PaCa-
2 
Pancreas Carcinoma ATCC ® 
#CRL-1420 
RPMI + 10% FBS + 
1% L-Glut + 1% 
Pen-Strep 
No 
Table 7: Cell lines and their characteristics. [ATCC ®: American Tissue Culture Collection]  
The above cell lines outlined in Table 3 were grown and maintained within a 37oC / 5% CO2 incubator. 
Cell lines were regularly inspected under light microscopy to monitor their health and confluence. Cell 
lines were sub-cultured (using trypsin) 2-3 times a week and frozen stocks made as required, for later 
use. Cell lines with passage numbers below 20 were maintained for experimental use. Results presented 
are for the cell lines of interest: Mia Pa Ca-2 and BxPC-3 only. These cell lines were used as they were 
easily and successfully passaged numerous times throughout my experiments, and as will be reported, 
showed contrasting expression to CA 19-9 antibody. 
2.2.2 Cryostorage of cells  
Confluent T75 flasks were passaged and cells centrifuged at 1000rpm for 10 minutes then pellets re-
suspended in complete medium + 5% DMSO (storage medium) in cryotubes.  Cryotubes were stored 
in -80oC overnight then transferred to -150oC liquid nitrogen. 
2.2.3 Recovery of cells from cryostorage 
Cryotubes were removed from liquid nitrogen and placed within a 37oC water bath. Once cells were 
thawed, they were immediately placed with a T25 flask containing warmed media. The following day 
Sumit Nandi  Treatment of pancreatic cancer using gemcitabine-loaded SPIONs 
 47 
the flask was washed with warmed PBS and fresh media replaced to remove the DMSO. Once cells 
were confluent, they were transferred to a T75 flask. 
 
2.3 Production of monoclonal antibodies from hybridoma culture 
Anti-CA 19-9 hybridoma was purchased from ATCC for culture and production of purified monoclonal 
antibody, which could be used for conjugated onto the SPION complexes. 
2.3.1 Culture of hybridoma 
The culture of the hybridoma is very similar to the cell culture methods of pancreatic cancer cells, 
except the hybridoma grow in suspension, so centrifugation is used in lieu of trypsin when passaging. 
The anti-CA19-9 hybridoma was maintained within a complete culture medium of DMEM with L-Glut; 
FBS (20%). The hybridoma is thawed using a 37oC water bath and generously sprayed with 70% 
ethanol. The cells are transferred to a 15 ml Falcon tube containing complete media. The cells then are 
centrifuged at 1000-1500rpm for 5min. These steps are performed as quickly as possible to prevent 
unnecessary stress to the cells. The media is removed, and the pellet re-suspended in 10ml fresh 
complete media and transferred to a T75 flask. The cells were maintained in a 37oC/5% CO2 incubator.  
2.3.2 Cryostorage of hybridoma cell lines 
This was performed using 5% DMSO in complete media with a cell count of 1x106 cells/ml. Cells were 
transferred to cryovials and immediately place in -80C freezer within a Mr Frostee ® container. The 
following day the cryovials transferred to liquid nitrogen (-150C) for long term storage. 
2.3.3 Passage and reducing amount of serum content in complete media 
Once growing well, the cells were sub-cultured 2-3 times a week at ratios between 1:2 and 1:4. The 
cells were passaged using centrifugation with supernatant removed and cells re-suspended in an 
appropriate volume of fresh media into a new T75 flask. Each passage step, the amount of serum content 
in the complete media was reduced, to allow for simpler and purer antibody to be produced downstream. 
For example, half the cells passaged were kept at 20% FBS baseline for stock and the other half grown 
in media with serum free media (plain DMEM) added to reduce the serum content to 10%. The serial 
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dilutions of serum continued until the amount of FBS was 2.5% - now ready for downstream 
applications.  
2.3.4 Antibody purification 
Cells in the low concentration of serum are centrifuged at 1500rpm for 10 minutes and re-suspended in 
the commercial provided binding buffer. The protocol for protein purification using Nab protein A spin 
columns was adhered to. 
2.3.5 Antibody production concentrations 
These were gathered using Nano Drop analyser against 450nm protein standard setting. 
2.3.6 SDS-Page 
To demonstrate successful production of a pure IgG antibody, the eluted fractions from the spin column 
process were loaded for SDS-page analysis against the relevant commercially available antibody. 
 
2.4 Functionalisation of SPIONs 
2.4.1 Carbodiimide-coupling chemistry 
An antibody was attached to the polymer surface of the SPION complex. This was achieved by using a 
reaction named carbodiimide-coupling using, in order, the chemicals 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and N-Hydroxysuccinimide (NHS). It is a commonly 
performed process often used to activate carboxylic acids towards amide formations. In these 
experiments, the carboxylic acid group lies on the polyoxazoline polymer and the amine group on the 
antigen binding site of an antibody. 
 
Figure 5: Carbodiimide-coupling chemistry to conjugate an antibody to the polymer coating of the SPION complex. 
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This process was kindly performed and demonstrated by Dr Michael Barrow and Dr Erol Hasan of the 
Department of Chemistry, University of Liverpool, and later performed by me. 
2.5 Different preparations of SPION manufactured. 
Due to the self-assembly process of manufacturing the tailor-made SPIONs a combination of 
components can be prepared. Additionally, the SPION can be functionalised with an antibody – this 
increases their size. Consequently, several nanoparticles can be produced for experimental use. I was 
able to attach different types of commercially available antibodies: isotype IgG and CA19-9. The 
various combinations of SPION manufactured is shown below in table 8. 
Nanohybrid complex Gemcitabine-loaded 
Antibody attached 
(functionalised) 
NH1.0   
NH1.2 ✓  
NH1.2:ISO ✓ Isotype IgG 
NH1.2:CA 19-9 ✓ Anti-CA-19-9 
Table 8: Different combinations of nanohyrbids synthesised. [NH = nanohybrid, 1 = 1mM/ml iron content; 2 = 0.2mg/ml 
gemcitabine pro-drug concentration]. 
 
2.6 MTS cytotoxicity assays 
MTS Assay uses a colorimetric method for the sensitive quantification of viable cells. It is based on a 
single ready-to-use reagent. The MTS assay can be used to assess cell proliferation, cell viability and 
cytotoxicity. 
2.6.1 Preparation of cells 
Confluent flasks of cells are trypsinised and centrifuged at 1000rpm for 5 minutes. A cell count 
performed using TC20™ Automated Cell Counter (Bio-Rad Laboratories Ltd, Hertfordshire, UK) to 
achieve a final cell concentration of 1x105 per ml. 100µL per well of cell-containing media plated into 
a 96-well plate with the outer wells usually filled with 100µL of media only, to prevent any evaporation 
effect. Therefore, each well contains 1x104 cells. One column of the plate is left bare and another filled 
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with media only – these are used as controls later. The plated cells are incubated at 37oC / 5% CO2 
overnight to be used the following day. 
2.6.2 Treatment / transfection of cells 
The next day, the media is removed and replaced with treatment media, at increasing dosage. Once 
complete, the plates are replaced into the incubator until the plate is ready to be analysed.  
2.6.3 Preparation of reagents 
All MTS assays were performed using EZ4U Cell Proliferation Assay (Biomedica, Oxford Biosystems, 
Oxford, UK). The kit contained a substrate (SUB) and activator (ACT). Firstly, these were warmed to 
room temperature and then the SUB dissolved in 2.5ml ACT. The mixed SUB and ACT solution then 
added to complete medium at 1:10 concentration and thoroughly mixed within a sterile trough – this 
suspension is added to the cells. The media from the 96-well plate is removed and discarded and 100µL 
of the above suspension containing the reagents is added to all the columns. 
2.6.4 Plate reading 
The cells are incubated again for up to 4 hours. Usually the plate reading at 2 hours is used for statistical 
analysis, as it tended to give the most consistent reading dependent on each cell line and treatment. The 
96-well plate of interest is read using a plate absorbance reader at 450nm with 620nm used as a 
reference. To improve the accuracy of the results absorbance from a substrate blank in medium is 
subtracted from all other values. The process is displayed in figure 6. 
 
Figure 6: Flow diagram showing the steps of plate reading for a MTS assay. 
The MTS cell proliferation assays were used to investigate the percentage of cell viability of cell lines 
against controls with no active chemotherapy agent (PBS or non-drug-loaded SPIONs) and with 
96-well plate 
incubated 
for 0 – 4 
hours, 
readings 
taken 
hourly.
Plate placed 
into plate 
reader and 
shaken for 
10 seconds.
Reading at 
450nm.
Reading at 
620nm.
Plate re-
intubated 
for further 
readings (if 
necessary).
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conditions with gemcitabine, either free or bound to SPIONs, at increasing concentrations. These 
experiments allowed calculation of each cell lines’ 50% inhibitory concentration or IC50. 
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2.7 Immunofluorescence 
2.7.1 Indirect immunofluorescence 
This method was utilised to assess the antigen expression of cell lines against a variety of antibodies, 
commercially bought or produced from hybridoma sub-culture. I thank Paul Sykes and Dr Carlos Rubbi 
(Lecturer in Cancer Biology, Molecular and Clinical Cancer Medicine) for aiding in the optimisation 
of my protocol. 
2.7.1.1 Cleaning coverslips 
Circular 13mm diameter [thickness 0.16 – 0.19mm] coverslips (Academy, University of Liverpool 
Stores) are firstly cleaned. Several coverslips can be cleaned at a time in an ethanol/hydrochloric acid 
mixture (200ml 70% EtOH + 6ml concentrated HCl) for at least one hour, with gentle periodic shaking. 
Following the de-greasing the coverslips are rinsed 10 times and transferred to a 10cm2 petri dish for 
use within a class II hood. The coverslips are rinsed again with 70% EtOH, which is then thoroughly 
aspirated and finally washed with tissue grade PBS prior to use with cells. If immediate use of the 
coverslips was not required, the coverslips was kept in 70% EtOH in a sterile container whilst working 
in a class II hood, for later use. 
2.7.1.2 Preparation of cells 
The de-greased and sterile 13mm diameter coverslips are carefully transferred, usually using curved 
Watchmakers forceps, from a 10cm2 petri dish to a sterile 24-well plate, with an individual coverslip in 
each well. Cells are added to each well at density 7x104/ml; 1ml of cells in complete medium is added 
to each well to completely immerse the coverslip. The 24-well plate is incubated overnight (27oC/5% 
CO2) to allow the cells to grow on the coverslip and for use the following day. 
2.7.1.3 Fixation of cells 
Before fixation, cells (grown on coverslips within a 24-well plate) are rinsed twice using tissue culture 
grade PBS. Fixation is performed using formalin solution, neutral buffered, 10% (Sigma-Aldrich Ltd, 
Dorset, UK) – 500µL is added to each well and gently shaken upon a table-top rocker at room 
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temperature for 10-15 minutes. The formalin solution is then aspirated and thoroughly rinsed with PBS 
+ 0.02% Tween-20 (Sigma-Aldrich Ltd, Dorset, UK) (PBS-T).  
2.7.1.4 Blocking  
A 2% bovine serum albumin in PBS-0.02% Tween solution is made and filtered through a 0.22m PES 
filter (Merck Millipore Ltd, County Cork, Ireland) to remove any protein aggregates, which diminish 
the final immunofluorescence (IF) image. Again, 500µL of the blocking solution is added to each well 
to immerse the coverslip and gently shaken for 30 minutes upon a table-top rocker at room temperature.
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2.7.1.5 Antibody incubation and washings 
All washes are using PBS-0.02% Tween and all antibodies are diluted in blocking solution (2% BSA in PBS-0.02% Tween). Following 30 minutes of blocking, 
the solution is washed off thoroughly. The antibody concentrations used for immunofluorescence are show in table 9. 
 
Table 9: Antibody concentrations for immunofluorescence. Shaded boxes are range of stock antibodies made in 1% BSA (based in 0.02% PBS-T) and used for immunofluorescence 
experiments. (IgG: immunoglobulin G, Hb: hybridoma)
Antibody Starting 
concentration 
Recommended 
dilution 
Dilution 
[Total protein in µg] 
   1:10 1:20 1:50 1:100 1:200 1:500 1:1000 
Anti-Ca19-9 [CA 19-9-203] 0.2mg/ml 1:50 – 1:100 - 8 4 2 1 0.4 0.2 
Anti-CEACAM7 [BAC2] 1mg/ml 1:100 - - 20 20 5 2 1 
ISO IgG 0.4mg/ml n/a - - 8 4 2 0.8 0.4 
Goat anti-mouse IgG, DyLight 
488 - secondary 
1mg/ml 1:200 – 1:1000 - - 20 10 5 2 1 
Hb CEA 0.03 – 0.1mg/ml n/a 3-10 1.5-5 0.75-
2.5 
0.37-
1.25 
- - - 
Hb CA 19-9 0.03 – 0.1mg/ml n/a 3-10 1.5-5 0.75-
2.5 
0.37-
1.25 
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2.7.1.5.1 Primary antibody 
Each antibody used is diluted appropriately, for example, dependent on commercial 
recommendations, in blocking solution. A hydrophobic surface is prepared using a parafilm-
wrapped 24-well plate lid. A 20µL drop of the diluted primary antibody is placed onto the 
parafilm surface. Coverslips are lifted from each well carefully, inverted, and placed onto the 
relevant primary antibody drop – this ensures the cells are in contact with the antibody. The 
primary antibody is incubated within a humid chamber for 1 hour.  
2.7.1.5.2 Secondary antibody 
Following primary antibody incubation, the coverslips are lifted from the parafilm surface, 
inverted, and replaced into the 24-well plate. The cells are washed for 8 minutes (4 x 2 minutes) 
with PBS-0.02% Tween. A fresh parafilm surface is adhered to the lid a 24-well plate and the 
same process used as per the primary antibody. Again, the secondary antibody is incubated for 
one hour within a humid chamber at room temperature, but in the dark, as the secondary 
antibody is fluorescent. The secondary antibody used in all the IF experiments is goat anti-
mouse IgG, DyLight-488 (Thermo Scientific, Rockford, IL, USA). 
2.7.1.5.3 DAPI staining 
Once both antibody incubations are complete, the coverslips are lifted from the parafilm, 
inverted, and returned to the 24-well plate. The coverslips are washed and rocked again for 8 
minutes as previously described, however, in the final rinse, is 0.1-0.5g/ml DAPI (Sigma-
Aldrich Ltd, Dorset, UK) added at dilution 1:5000.  
2.7.1.5.4 Mounting 
Mowiol® 4-88 (Sigma-Aldrich Ltd, Dorset, UK) is used as the mounting medium, with the 
addition of 0.5g/ml DAPI. For each coverslip, 5l of mounting medium is placed onto a 
rectangular Superfrost ® Plus glass slide (Thermo Scientific, Cramlington, UK), usually three 
coverslips can be accommodated on one glass slide. The coverslips are carefully lifted from the 
24-well plate, excess liquid dried onto blue roll and placed onto the drop of mounting medium. 
Sumit Nandi  Treatment of pancreatic cancer using gemcitabine-loaded SPIONs 
 56 
The glass slides are placed at 4oC overnight to allow the mounting medium to harden. The 
following day the coverslips are held in place onto to the glass slide using toluene-based 
lacquer. 
2.7.2 Fluorescent microscopy 
All IF images were obtained using Zeiss Axio Imager Z1 (Carl Zeiss Ltd UK, Cambridgeshire, 
UK). This microscope is suited for comprehensive high-resolution 3D evaluation of fixed cells. 
Prepared slides are cleaned with 70% EtOH and are visualised under the microscope to a 
maximum magnification of 63x with immersion oil Immersol 518 F fluorescence free (Carl 
Zeiss Ltd UK, Cambridgeshire, UK) to visualise single cells. DAPI (nuclear staining) and 
488nm (secondary antibody) channels are used for all IF work. Commonly Z-stack images were 
obtained. 
2.7.2.1 MicroManager 
Images directly from the Zeiss Axio Imager Z1 were saved using MicroManager 
(https://www.micro-manager.org/wiki/Download_Micro-Manager_Latest_Release) version 
1.4.20. This software allowed for exposure time, binning, Z-stacks, channels, magnification 
and brightness all to be altered to improve image capture. 
2.7.2.2 ImageJ 
Saved stack files from fluorescent microscopy were manipulated using software ImageJ 1.48 
(imagej.nih.gov/ij/download/). This allowed for colouring of channels (blue for DAPI; green 
for 488nm fluorescence). 
 
2.8 Experiments using Operetta® CLS High-Content Analysis System  
These protocols were entirely novel equipment and components used, therefore it required 
optimisation guided from previous attempts. These experiments were performed by me, Ms 
Hannah Murphy (MRes student) and Ms Sarah Brumskill (PhD student at Redx Pharma at 
University of Liverpool).  
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2.8.1 Visualisation of receptor-mediated endocytosis of SPIONS in a 2D model  
MIaPaCa-2 cells were plated at various cell densities in 96 well plates ranging from 1x103 cells 
per well to 1x106 cells per well. Cells were incubated for 48 hours to form a monolayer. Hoechst 
[1mg/ml] [excitation rate- 350nm and emission rate-461nm] was diluted with PBS to various 
concentrations [2µg/ml, 5µg/ml, 10µg/ml and 20µg/ml] and incubated at room temperature for 
7 minutes. Cells were washed thoroughly, and SPIONs were added at dilution of 1:10, 1:20, 
1:50 and 1:100. The plate was placed onto the Operetta CLS High-Content Analysis System 
(Perkin Elmer, Llantrisant, UK) and incubated for 17 hours. Cells were visualised and analysed 
using Harmony ® High Content Imaging and Analysis Software (Perkin Elmer, Llantrisant, 
UK).  
2.8.2 Formation of condensed spheroids 
BxPC-3 cells were plated at a density of 1.0x103 cells per well using 96 well ultra-low adherent 
(ULA) plates (Thermo Scientific, Cramlington, UK). To visualise the formation of the 
spheroid, the ULA plate was immediately placed on the Operetta CLS High-Content Analysis 
System, where the cells remained incubated at 37°C/5% CO2. In our experiments, we utilised 
the Operetta® and its the ability to perform confocal imaging on live cells. Using the Harmony 
® High Content Imaging and Analysis Software, we were able to view the continual formation 
of spheroids, over 12 hours.  
2.8.3 Dissociation of formed spheroids using gemcitabine-loaded SPIONs 
Spheroids were formed using the aforementioned protocol. Gemcitabine-loaded SPIONs were 
diluted at a concentration of 10% and added to the spheroids. DMEM phenol red free media 
(Gibco Life Technologies) was used in all spheroid formation experiments. The spheroids (with 
the transfected SPIONs) were visualised for 13 hours using the Operetta.  
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2.9 Artificial circulation experiments 
These experiments were performed in close collaboration with Professor John Hunt (Head of 
Unit, Musculoskeletal Biology, University of Liverpool). The purpose of these experiments 
was to investigate the efficiency of the cytotoxicity of gemcitabine-loaded SPIONs within an 
artificial flow system, mimicking a blood circulation. It will serve as a pre-cursor to in vivo 
experimentation.   
2.9.1 Manufacture of flow T25 flasks 
Cell culture 25cm2 flasks with plug seal caps (VWR, Leicestershire, UK) were modified by 
drilling two holes either side of the flask and securing a threaded female Luer connector in the 
defects created. The modification of flasks was kindly made by Mr James Blackhurst (Engineer 
for the Clinical Engineering Group, Institute of Ageing and Chronic Disease) at the Central 
University Workshop, Ground Floor Duncan Building, shown in figure7. The completed flow 
T25 flasks are sterilised with 70% EtOH, irradiated under ultraviolet light and washed with 
PBS prior to any introduction of cells. 
 
 
 
 
 
2.9.2 Preparation of pancreatic cancer cells 
Pancreatic cancer cell lines (MIA PaCa-2 or BxPC-3) were seeded into sterilised flow T25 
flasks at density 2x106 cells per flask (or 4x105 cells/ml with 5ml of media per flask). The cells 
are grown overnight in a 37oC/5% CO2 incubator until at least 90% confluence, forming a dense 
monolayer – which is to be used for the flow experiments. Before exposure to any treatment, 
the monolayer is imaged using light microscopy. 
Figure 7: Figure demonstrating specifically modified T25 flask 
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2.9.3 Construction of flow system 
The entire system (except the peristaltic pump) is maintained within a large 37oC/5% CO2 
incubator with the Musculoskeletal Biology laboratory on the ground floor of the Duncan 
Building. All component parts are autoclaved (5th floor UCD Building, University of Liverpool) 
prior to use with cellular material.  
2.9.3.1 Peristaltic pump and tubing 
A laboratory bench peristaltic pump was used, 323D peristaltic pump with a three-roller 313D 
flip-top pump head (Watson-Marlow Ltd, Cornwall, UK). Throughout the whole system 1.6mm 
gas permeable tubing was used (Watson-Marlow Ltd, Cornwall, UK). The peristaltic pump 
drove at a flow rate between 80 to 120rpm. 
2.9.3.2 Set-up of flow system 
The peristaltic pump controls the flow of media around the circuit. A 250ml media bottle (DWK 
Life Sciences, Mainz, Germany) contained 250ml media (with or without nanoparticle 
treatment) is connected to the peristaltic pump via 1.6mm gas permeable tubing. Distal to the 
pump the media is split into two parallel circuits through the flow T25 flasks containing 
pancreatic cancer cells. One T25 flask has two magnets (University of Liverpool Stores) 
underneath it. This creates a variable of cells exposed to a magnetic field and cells without a 
magnetic field. Once the media has flowed through both flasks, over each cell monolayer, the 
media flows back into the media bottle, to start the circuit again. The whole circuit is exposed 
to the incubator’s environment (namely 5% CO2) via a 0.22µm filter, to prevent environmental 
micro-organisms entering the system. The diameter and length of tubing through each limb of 
the parallel circuit is constant. The completed system is shown in figure 8. 
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Figure 8: Figure demonstrating set-up of artificial circulatory model. Demonstrating the continuous 250ml 
media within the media bottle and two T25 flasks in continuous circuit with the nearest flask in the image 
with two magnets taped on its underside. G-SPIONs = gemcitabine-loaded SPIONs. 
2.9.4 Flow experiments 
Prior to attaching the flow T25 flasks to the circuit, the tubing is flushed with 70% EtOH and 
then PBS using a different media bottle. The flasks and media-containing bottle are plumbed 
into the circuit and the peristaltic flow commenced. The experiment is ran for a certain time 
period with the below variables in table 10. 
Time point Treatment Magnet Flow 
16 / 24 / 48 / 72 hours Media with 2% 
nanoparticle treatment or 
media only. 
Magnetic field 
underneath flask present 
or absent. 
Exposed to 80rpm 
flow of media or 
static only 
Table 10: Variables pancreatic cancer cells are exposed to during experiments with an artificial circulatory 
model. 
2.9.5 Cell work following flow experiment 
After a certain time point, the flow experiment is discontinued and the specially manufactured 
T25 flasks are un-plumbed and are left in a 37oC/5% CO2 incubator overnight.  
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2.9.5.1 Extraction of media from T25 flask 
The following day the media residing in the flask is removed carefully (not to disturb any 
adherent cells) and centrifuged at 600g for 10 minutes. The supernatant (1ml) of the spun-down 
media is removed, placed in a labelled cryovial and stored at -80oC. This supernatant will be 
used later in a lactate dehydrogenase (LDH) assay, as a measure of cell lysis occurring during 
the experiment within the flask. 
2.9.5.2 Light microscopy 
The cell monolayer within the flask is gently washed with warmed PBS, to remove clumps of 
cells, and imaged under the light microscope. Therefore, both pre-flow and post-flow light 
microscopy images are obtained and can be used for comparison. 
2.9.5.3 DAPI staining 
Once light microscopy images are taken, the washed cells are fixed using formalin solution, 
10% (Sigma-Aldrich Ltd, Dorset, UK) for 15 minutes on a table-top rocker. Following that, the 
formalin solution is washed off with PBS three times, with the third wash step containing DAPI 
(Sigma-Aldrich Ltd, Dorset, UK) at dilution 1:1000 for 10 minutes on a table-top rocker. The 
PBS with DAPI is removed and the cells washed further with PBS. Finally, the cells are stored 
in PBS, in the dark, at 4oC, for later use in fluorescent microscopy to visualise the uptake of 
SPION within cells. 
2.9.6 Lactate dehydrogenase assay 
This was performed to evaluate of cell death or cytotoxicity by the quantification of plasma 
membrane damage, by measuring the enzyme lactate dehydrogenase (LDH), which is released 
into cell culture medium upon damage of the plasma membrane. The media obtained and cryo-
stored from the flow experiments was used in the LDH assay. The protocol from the LDH-
cytotoxicity assay Kit II (Abcam, Cambridge, UK) was rigidly followed. This protocol utilised 
the advanced WST reagent for the detection of LDH released from damaged cells. The assay 
uses an enzymatic coupling reaction where LDH oxidises lactate to generate reduced 
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nicotinamide adenine dinucleotide (NADH), which consequently reacts with WST to generate 
a yellow colour. The intensity of the colour correlates directly with the number of cells lysed 
within the media.  
2.9.7 Fluorescent microscopy of remaining cellular monolayer 
The remaining fixed monolayer of cells were visualised under the Zeiss Axio Imager 
Z1microscope (Carl Zeiss Ltd UK, Cambridgeshire, UK) to obtain fluorescent microscopy 
images. This was performed to show the cellular uptake of the rhodamine-labelled SPIONs in 
pancreatic cancer cells, the nuclei already stained using DAPI. 
 
2.10 Statistical Analysis 
All statistical analysis of the laboratory-based experiments was performed using software 
GraphPad Prism 5.0. This software was also used to generate relevant publication quality tables 
and graphs.
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3 Results I: Nanoparticles 
3.1 Characteristics of SPIONs manufactured 
3.1.1 Size of SPIONs manufactured 
Dynamic light scattering (DLS) technique was used to determine the size of the gemcitabine-loaded 
SPIONs before and after the attachment of an CA 19-9 antibody. The average diameter of particle 
manufactured without antibody conjugation was 143.7nm and with an antibody attachment was 
197.9nm – see figures 9 and 10.  
 
Figure 9: DLS curve demonstrating average SPION size without CA 19-9 antibody attachment. The average value is 
143.7nm in diameter. (n=5) 
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Figure 10: DLS curve demonstrating average SPION size with CA 19-9 antibody attachment. The average value is 
197.9nm in diameter. (n=5) 
These experiments were kindly performed by Dr Mike Barrow, Department of Chemistry, University 
of Liverpool. 
3.1.2 Solubility and stability of SPIONs manufactured 
The manufactured SPIONs are successfully stable in solution of either PBS or distilled water for several 
months. SPIONs loaded with gemcitabine maintained their cytotoxicity if used within three months of 
production. The SPIONs used for cell experiments were stored in PBS and kept refrigerated at 4oC 
before use. 
3.1.3 High performance liquid chromatography 
The range of gemcitabine pro-drug that is attached to the SPION complex had a mean of 8.15x10-
2mg/ml and iron concentration of 120.15µg/ml. 
 
3.2 Magnetic qualities 
The superparamagnetic properties of the SPIONs were proven, with the SPIONs aggregating over the 
area of an external magnet. The SPIONs aggregated in the desired area by 10 minutes. This has been 
described previously in experimentation performed by Mr Thompson Gana and Mr Paul Sykes as 
precursor work and not repeated by me. 
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3.3 Antibody attachments 
3.3.1 Production and purification of monoclonal antibodies 
The antibody produced from the cultured anti-CA19-9 hybridoma was positively purified and stored. 
They were successfully used in later experimentation (results shown in following chapter). 
3.3.2 SDS-page for anti-CA 19-9 antibody 
To demonstrate successful production of a pure IgG antibody (figure 11), the eluted fractions from the 
spin column process were loaded for SDS-page analysis against the relevant commercially available 
antibody. 
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Figure 11: SDS page showing successful production and reduction of pure IgG produced from anti-CA 19-9 
antibody hybridoma 
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3.4 Summary 
These results demonstrate that we were able to make consistent ‘raw materials’ for further translational 
experiments. The SPIONs produced were colloidally stable, of a consistent size under 200nm (which 
as earlier described is of interest for the clinic) and loaded with a adequate concentration of gemcitabine 
pro-drug. In addition, the cells grown throughout the experiments, were consistently of high quality, 
ensuring free of infection (including mycoplasma) and showed correct genotype. Finally, the antibodies 
to be used for targeting ligands for the SPIONs were successfully manufactured and repeatedly attached 
onto the SPION. 
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4 Results II: Cytotoxicity of pancreatic cancer cell lines in 2D culture 
4.1 Cell Culture 
4.1.1 Successful culture of pancreatic cancer cell lines 
A variety of pancreatic cancer cell lines were used for my experiments and continuously successfully 
passaged. In the whole, these were free from infection, whenever infection was suspected given its 
microscopic appearances, they were discarded. For the experiments I used BxPC-3 and Mia Pa Ca-2 
cells. The following figures 12 and 13 demonstrate light microscopy images of healthy cells that were 
successfully cultured shown against stock images from ATCC (American Type Culture Collection). 
4.1.2 BxPC-3 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Light microscopy image of healthy high density BxPC-3 cells (right) successfully 
cultured shown against stock commercial image (left). 
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4.1.3 Mia Pa Ca-2 cells 
 
 
 
 
 
 
 
4.2 Indirect immunofluorescence 
This was performed to assess the antigen status of common pancreatic cancer cell lines. Mia Pa Ca-2 
and BxPC-3 cells were subjected to a variety of antibodies. This included a stock generic isotype IgG, 
commercially available or stock CA19-9 (stCA19-9) and CA19-9 antibody cultured and purified from 
a hybridoma. The following figures show fluorescent microscopy images obtained using Zeiss Axio 
Imager Z1 (Carl Zeiss Ltd UK, Cambridgeshire, UK). These experiments were initially performed by 
my colleague Mr Paul Sykes and were successfully replicated. The antigen expression for CA 19-9 for 
both Mia Pa Ca-2 and Bx PC-3 cells are shown in figures 14 and 15. 
 
 
 
 
 
 
 
Figure 13: Light microscopy image of healthy high density Mia Pa Ca-2 (right) successfully 
cultured shown against stock commercial image (left). 
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4.2.1 Mia Pa Ca-2 cells show no expression for CA19-9 antibodies 
Antibody: 
Isotype IgG 
 
stCA19-9 
 
HbCA19-9 
  
 
Figure 14: Fluorescent microscopy showing the indeterminate expression of Mia Pa Ca-2 cells to isotype IgG antibody, 
but no expression against both the stock (stCA 19-9) and hybridoma-produced CA19-9 (HbCA19-9) antibody. 
Fluorescent microscopy images at x63 magnification (n=3). 
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4.2.2 BxPC-3 cells are strongly positive expressive for CA19-9 antibodies 
Antibody: 
Isotype IgG 
 
stCA19-9 
 
HbCA19-9 
 
 
Figure 15: Fluorescent microscopy showing the indeterminate expression of BxPC-3 cells to isotype IgG antibody, but 
strong expression against both the stock (stCA 19-9) and hybridoma-produced CA19-9 (HbCA19-9) antibody. 
Fluorescent microscopy images at x63 magnification (n=3). 
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4.2.3 Antigen expression of Mia Pa Ca-2 and BxPC-3 cell lines 
The opposing antigen expressiveness of these cell lines against CA 19-9 antibodies suited them to be 
ideal to use in forward experimentation to examine the antibody mediated uptake of our nano-
complexes. 
 
4.3 MTS assay results 
4.3.1 Treatments used 
The MTS cell proliferation assays were used to investigate the percentage of viability of cell lines 
against controls with no active chemotherapy agent (PBS or non-drug-loaded SPIONs) and with 
conditions with gemcitabine, either free or bound to SPIONs. Finally, against nano-complexes loaded 
with gemcitabine and functionalised with an antibody – either a non-specific isotype IgG or a targeting 
CA 19-9 antibody. These experiments allowed calculation of each cell lines’ 50% inhibitory 
concentration or IC50 after 72 hours of applied treatment. 
4.3.2 No reduction in cell viability without gemcitabine 
No cytotoxic effect was seen without gemcitabine, either with PBS or nano-complexes without 
gemcitabine loading. This highlighted the non-toxic effect of the nanocomplex alone. Data not shown. 
4.3.3 Mia Pa Ca-2 cells 
Mia Pa Ca-2 cells were proven to be non-expressive for CA 19-9 antigen in earlier immunofluorescence 
experiments described in 4.2.1. They were prepared as per section 2.6 and subjected to the above 
treatments described in 4.3.1. Figure 16 demonstrates the different cytotoxicity effects to the cells when 
subjected to differing SPION treatments for a period of 72 hours. It demonstrates that the IC50 value 
does not change despite what treatment the cells are exposed to. The non-antigen expressive cells are 
not influenced by any antibody attachment: when exposed to nanohybrids with a specific CA 19-9 tag 
(3,090nM) versus nanohybrids with a non-specific isotype tag (3,535nM) or non-antibody tagged 
nanohybrids (4,051nM). The cells were exposed to the different treatments for 72 hours before being 
analysed for MTS cytotoxicity assays. Finally, when plain gemcitabine was used the IC50 was only 
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41.79nM – data curve not shown due to scaling. These results were not statistically significant with a 
p-value of 0.27.   
4.3.4 BxPC-3 cells 
Figure 17 demonstrates the different cytotoxicity effects to the cells when subjected to differing 
treatments. The IC50 value falls considerably when exposed to nanohybrids with a specific CA 19-9 tag 
(354nM) versus nanohybrids with a non-specific isotype tag (1,175nM) or non-antibody tagged 
nanohybrids (1,123nM). The cells were exposed to the different treatments for 72 hours before being 
analysed for MTS cytotoxicity assays. Finally, when plain gemcitabine was used the IC50 was only 
4.99nM – data curve not shown due to scaling. These results were statistically significant with a p-value 
of <0.001.  This data proves that reduced cell viability can be accelerated significantly when targeted 
with a specific antibody-tagged vehicle carrying chemotherapy agent against antigen expressive cells, 
such as Bx-PC-3. Finally, it appears that the BxPC-3 cell line is more chemo-sensitive to gemcitabine, 
as much lower concentrations of gemcitabine was required to cause significant cell death with the same 
cell density as the Mia Pa Ca-2 cell line. 
 
4.4 Summary  
The experiments performed against pancreatic cancer cells in vitro in 2D culture prove that cell death 
can be accelerated effectively by using a specific antibody-tagged gemcitabine-loaded SPION. 
Furthermore, the experiments demonstrated that the gemcitabine loaded onto the nanohybrids is the 
only chemotoxic agent the cells are exposed to. This was encouraging results and would lead to further 
study of the cells; Mia Pa Ca-2 (CA 19-9 antigen negative) and BxPC-3 (CA 19-9 antigen expressive) 
in both 3D and circulatory models. 
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Figure 16: MTS cytotoxicity curves and table demonstrate no statistically significant alteration in the IC50 of Mia Pa Ca-2 cells when treated with either  nanohybrids (NH), non-specific 
isotype antibody-tagged nanohybrids (NH:ISO) or CA 19-9 antibody-conjugated nanohybrids (NH:CA 19-9). Gemcitabine curve is not shown. 95% CI shown. (n=5; p=0.27) 
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Figure 17: MTS cytotoxicity curves and table demonstrate statistically significant decrease in the IC50 of BxPC-3 cells when treated with CA 19-9 antibody-conjugated nanohybrids 
(NH:CA 19-9) in comparison to nanohybrids (NH) and non-specific isotype antibody-tagged nanohybrids (NH:ISO). Gemcitabine curve is not shown. 95% CI shown (n=6; p<0.001) 
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5 Results III: Cytotoxicity of pancreatic cancer cell lines using  
Operetta® CLS High-Content Analysis System (including against 
formed spheroids) 
5.1 Visualisation of receptor-mediated endocytosis  
5.1.1 SPIONs enter Mia Pa Ca-2 cells and are targeted to the nucleus 
We were able to take real-time confocal imagery using the Operetta® CLS High-Content Analysis 
System and analysed them using the Harmony ® High Content Imaging and Analysis Software. We 
were able to run the experiment for a total of 17 hours, however, we found that 2 hours after transfection, 
the SPIONs entered the cells and after 4-6 hours they begin to target the nucleus (figure 18 C-D). Up to 
10 hours after transfection, the SPIONs have completely engulfed the cells and only they are visible 
(figure 18 E-F).  
 
5.2 BxPC-3 form tightly packed spheroids 
We experimented with both Mia Pa Ca-2 and BxPC-3 cells and found the BxPC-3 cells formed tight 
spheroids, probably as they tend to grow with more confluence in normal 2D culture within a T75 flask 
as shown in section 4.1. We were able to successfully visualise the formation of the BxPC-3 spheroid 
over a period of 10 hours in the Operetta® CLS High-Content Analysis System. The formation of the 
spheroid is shown in figure 19. 
 
5.3 Addition of gemcitabine-loaded SPIONs causes dissociation of tight formed spheroids  
Once spheroid formation was optimised, the gemcitabine-loaded SPIONs were transfected onto the 
spheroids, to assess their effect on the tightly packed structure. We were able to successfully visualise 
the effects of the gemcitabine-loaded SPIONs on the BxPC-3 spheroid over a period of 10 hours in the 
Operetta® CLS High-Content Analysis System. The formation of the spheroid is shown in figure 19. 
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Figure 20 shows that over a 14-hour period there is complete dissociation of the spheroid visually 
indicating cell death.  
 
Figure 18:  MiaPaCa-2 cells treated with gemcitabine-loaded SPIONS. SPIONs visualised on the Operetta® CLS High-
Content Analysis System, and images were produced using Harmony ® High Content Imaging and Analysis Software. 
Images represent cells at [A] 0 hours [B] 2 hours [C] 4 hours [D] 6 hours [E] 8 hours [F] 10 hours after incubation in 
Operetta. Blue= Hoescht [2ug/ml] representing cells’ nuclei. Yellow= Rhodamine, representing SPIONs. (n=3)  
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Figure 19: Confocal microscopy imagery demonstrating formation of tightly condensed BxPC-3 spheroids, visualised 
using Operetta® CLS High-Content Analysis System, and images were produced using Harmony ® High Content 
Imaging and Analysis Software. Images represent cells at [A] 0 hours [B] 2 hours [C] 3.5 hours [D] 6 hours [E] 8 hours 
[F] 10 hours after incubation within the Operetta® CLS High-Content Analysis System. Image magnification x150. 
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Figure 20:  Confocal microscopy imagery demonstrating the dissociation of the tight spheroid using gemcitabine-loaded 
SPIONS. Cells initially incubated for 2 hours. Images represent [A] 2 hours [B] 5 hours [C] 8 hours [D] 10 hours [E] 
12 hours [F] 14 hours after incubation. Visualised using the Operetta® CLS High-Content Analysis System, and images 
were produced using Harmony® High Content Imaging and Analysis Software. Yellow=rhodamine incorporated 
within SPION. Image magnification x30 
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5.4 Summary 
These experiments involving the Operetta® CLS High-Content Analysis System were entirely novel, 
in terms of the use of this piece of equipment to demonstrate real time cell death after transfection with 
gemcitabine-loaded SPIONs. They certainly needed a great deal of optimisation especially in 
determining the ideal density of cells to use to form a spheroid initially. Unfortunately, we would have 
liked to perform further experiments with more cell types. 
 
As a result, the conclusions drawn from these experiments are primarily to exhibit the cell death or 
destruction of a tightly formed cell spheroid, which would be more in-keeping with a solid in vivo 
tumour after treatment with the gemcitabine-loaded SPIONs.  
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6 Results IV: Cytotoxicity of pancreatic cancer cell lines (artificial 
circulation) 
6.1 Variables 
The artificial circulation model experiments were carried out as described in section 2.9. They created 
several variables within the experiments to investigate the use of the differing treatments against the 
pancreatic cancer cells. These are outlined in Table 10 as per section 2.9, however, will be repeated for 
ease (Table 11). 
Time point Treatment Magnet Flow 
16 / 24 / 48 / 72 hours Media with 2% 
nanoparticle treatment or 
media only. 
Magnetic field 
underneath flask present 
or absent. 
Exposed to 80rpm 
flow of media or 
static only 
Table 11: Variables pancreatic cancer cells are exposed to during experiments with an artificial circulatory model. 
 
6.2 Cell lines used 
As these experiments were entirely novel and had never been attempted before, a lot of optimisation 
was required. We found that the Mia Pa Ca-2 cell line grew well and were resilient enough to withstand 
the flow experimentation. Therefore, efforts were concentrated on using this particular cell line to 
investigate the magnetic properties of the gemcitabine-loaded SPIONs to increase cell death over time. 
We experimented extensively with the BxPC-3 cell line, but unfortunately found that the artificial flow 
element of the experiments gave a detrimental outcome to their normal growth pattern. As we found 
earlier in 2D culture, much lower concentrations of gemcitabine were required to cause cytotoxicity in 
the BxPC-3 cell line, this may have had a bearing on the potential results that we were unable to obtain 
for that particular cell line. 
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6.3 Light microscopy  
6.3.1 Destruction of monolayers when subjected to gemcitabine-loaded SPION treatment; especially 
over a magnetic field 
The cell monolayer at each time point within the experiment was imaged under the light microscope. 
This was to obtain simple images that could be used to see the progression of potential cell death. The 
light microscopy images demonstrate that the cell monolayer is destroyed quicker when the treatment 
has been applied over a magnetic field when transfected with gemcitabine-loaded SPIONs. There is a 
marked difference between where the magnetic field is at its strongest (centrally) compared to both 
peripherally obtained images and in cell monolayers without a magnetic field at all. These results were 
reproduced 3 times and shown in figure 23. 
6.3.2 No destruction of the cell monolayer was seen on light microscopy without treatment with 
gemcitabine-loaded SPIONs 
Light micrographs of the cell monolayer obtained at the same time points when only subjected to media 
only instead of treatment with gemcitabine-loaded SPIONs, did not show any significant destruction or 
cell death. This is the control arm of the experiments. This indicates that no cytotoxic effect was seen 
without gemcitabine or that the cells were being damaged by the flow system itself. This is shown in 
figure 22. 
 
Figure 21: Light micrographs of cellular monolayers subjected to phosphate-buffered saline only within the artificial 
circulatory model. Images taken before commencing flow and after various time points. Panels demonstrate no 
significant destruction of the cell monolayer over time. 
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Figure 22: Light micrographs of cellular monolayers subjected to treatment with gemcitabine-loaded SPIONs. Images taken before commencing flow and after various time points. Panels 
demonstrate increased monolayer destruction over time and with a magnetic field in-situ. MAG = magnetic field in-situ; images taken at both the central aspect of the flask where the magnet 
in situated and periphery of the flask where the magnetic field is weaker. All micrographs at magnification 20x. n=3 
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6.4 Co-localisation fluorescent microscopy  
6.4.1 Demonstrated uptake of gemcitabine-loaded SPIONs by cells after 72 hours of circulation  
Following treatment with gemcitabine-loaded SPIONs, the cell monolayer was imaged using co-
localisation fluorescent microscopy. This demonstrated that the SPIONs were up taken by the cells, 
furthermore, showed that the SPIONs are being drawn to the cells within the artificial circulation model. 
The images obtained were taken from the periphery of the flask or in experiments without a magnetic 
field, as after 72 hours the cell monolayers over a magnetic field centrally were essentially destroyed 
and therefore were unable to be imaged effectively. Nevertheless, the fluorescent microscopy obtained 
was encouraging showing that even after 72 hours, SPIONs were still in circulation and adherent to 
cells. This is demonstrated in figure 24. 
 
Figure 23: Co-localisation fluorescent micrograph of Mia Pa Ca-2 cellular monolayer subjected to 72 hours of  
gemcitabine-loaded SPION treatment. Blue=DAPI nuclear staining of cells; red=rhodamine tagged SPIONs. 
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6.5 LDH assay results 
6.5.1 No significant cell death demonstrated in control arm in both static and flow conditions 
This was further evidence that the active treatment for cell death is gemcitabine. The control arm (media 
only) did not show any significant increased cell death despite the other variables in the experiments: 
use of a magnetic field, time points or use of a flow system. The LDH assay results are represented in 
figure 25 B and D, where the higher the optical density the greater the cell death. 
6.5.2 Use of magnetic field has significant increased cell death in static conditions at early time point 
At the 16-hour time point, a statistically significant increase in cell death in static conditions 1.094nm 
with the magnetic field against 0.752nm without the magnetic field; p<0.05. After the 16-hour time 
point, there was no statistically significant difference in cell death with the use of a magnetic field. This 
is represented in figure 6.4 C, where the higher the optical density the greater the cell death. 
6.5.3 Use of magnetic field demonstrated significant increased cell death within a flow system 
There was an increased in cell death when cells were subjected to gemcitabine-loaded SPIONs within 
the flow system with the use of a magnetic field. At the 16 and 24 hour time points, the results are 
statistically significant, these are summarised in table 12. 
Time point (hours) 
Optical density (nm) 
p- value 
Magnetic field 
No magnetic 
field 
16 0.751 0.139 <0.001 
24 0.798 0.226 0.02 
48 1.716 1.375 0.10 
72 1.645 1.330 0.11 
Table 12: Summary of LDH assay results from flow experiments using gemcitabine-loaded SPION treatment with or 
without the use of a magnetic field. (nm=nanometre) 
Furthermore, the results are represented in graphical form in figure 25 A and highlighted in figure 26. 
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Figure 24: Results from LDH assay performed on all conditions tests. Higher optical density indicates increased cell death. [A] confirms cell death effects of gemcitabine-loaded SPIONs; 
potentiating effect of magnet in early time points with flow and little effect of magnet in static experiments. n=3 for all experiments. Treatment = 2% gemcitabine-loaded SPIONs. 
Control = media only. MAG=use of magnetic field. (nm=nanometre) ** p<0.001; *  p<0.05.    
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Figure 25: Results from LDH assay highlighting the increased cell death from magnetic targeting at early 
time points in a flow system. n=3. Higher optical density indicates increased cell death. Treatment = 2% 
gemcitabine-loaded SPIONs. MAG=use of magnetic field. ** p<0.001; *  p<0.05.  
 
 
6.6 Summary 
The artificial circulation model experiments were very encouraging in demonstrating some 
important negatives. Firstly, that again only the gemcitabine-loaded SPIONs (indirectly 
gemcitabine) can cause cytotoxicity of the cells. Secondly, that the flow system that the cells 
are being subjected does not cause harm to them, as shown in the control arm of the 
experiments. Promisingly, we have demonstrated that the gemcitabine-loaded SPIONs can 
successfully be drawn from a circulatory model and destroy cell monolayers. This effect is 
definitely potentiated by the magnetic targeting mechanism and has its greatest effect at early 
time points (16 and 24 hours) and although has reducing effect, is still present by 72 hours, 
although not statistically significant.  
 
** * 
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7 Discussion 
7.1 Interpretations 
The results presented are predominantly novel experiments into producing cytotoxic effects on 
pancreatic cell lines using a multifunctional superparamagnetic iron oxide nanoparticles 
(SPIONs) loaded with gemcitabine. We have shown in a variety of modalities that the 
manufactured SPIONs are successful in causing cytotoxic effects to desired cells. Importantly, 
it has been demonstrated that it is only the chemotherapy agent (gemcitabine) alone that is 
causing the cell damage. By successfully growing specific cancer cell lines for our experimental 
purposes we have shown the capabilities of the manufactured SPIONs as published by Olariu 
et al [137]. The pancreatic cancer cells were effectively manipulated to demonstrate the SPIONs 
ability to cause cytotoxic effects in three differing environments: in 2D culture, 3D culture and 
within a flow system. This is particularly encouraging as it demonstrates that the SPIONs are 
adaptable to the environment they have been subjected to and still cause the desired effects – 
causing cell damage to cancer cells.  
7.1.1 Successful uptake of gemcitabine-loaded SPIONS to cancer cells 
With the use of co-localisation fluorescent microscopy, we have demonstrated successful 
cellular uptake – with endocytosis – in both 2D and 3D models. Furthermore, this was shown 
in real-time confocal imaging using the Operetta® CLS High-Content Analysis System and 
Harmony ® High Content Imaging and Analysis Software. The real-time imaging showed 
maximal effect at around 4-6 hours without any active targeting mechanism. 
7.1.2 Accelerating effects of gemcitabine-loaded SPIONs 
Furthermore, two methods of active targeting of the SPIONs have been demonstrated. Both 
have indicated an improvement in the absolute reduction in the cell viability of the treated 
pancreatic cells and also accelerating the process, as proven by the use of MTS assays.  
Sumit Nandi  Treatment of pancreatic cancer using gemcitabine-loaded SPIONs 
 88 
7.1.2.1 Attaching CA 19-9 antibody 
Firstly, by attaching a specific target ligand in the form of an anti-CA 19-9 antibody onto the 
surface coating of the nano-complex, when targeted against a CA 19-9 antigen expressive cell 
line, such as BxPC-3, as used in these experiments. Conversely, the antibody targeting showed 
no reduction in cell viability against the Mia Pa Ca-2 cell line, which was proven to be non-
expressive of CA 19-9 antigen. Both these cell lines’ antigen expressivity was repeatedly 
demonstrated using indirect immunofluorescence.  
7.1.2.2 Magnetic targeting 
Secondly, by exploiting the unique magnetic qualities of SPIONs, we were able to draw the 
SPIONs to accelerate cell damage to the pancreatic cancer cells. This was particularly of 
interest as this was tested within the artificial circulatory model. These results add to the prior 
work of my colleague, Mr Paul Sykes, who had successfully demonstrated the aggregation of 
SPIONs over a static magnet in 2D culture. We both demonstrated that the magnetic targeting 
effect was relatively swift with the statistically significant benefit in reducing cell viability 
occurring by 24 hours within a flow system. Finally, the magnetic targeting results were against 
a cell line (Mia Pa Ca-2) that was non-expressive for CA 19-9 antigen.  
7.1.3 Versatility of gemcitabine-loaded SPIONs 
As described, the SPIONs were successful in differing environments plus independently 
demonstrated an effective benefit with two methods of active targeting. These attributes are 
important going forward for their potential application in the clinic [9, 52], which is discussed 
in more detail below. 
 
7.2 Implications 
The ultimate purpose of these experiments and the results is to showcase the gemcitabine-
loaded SPIONs effects in vitro, in order to translate the findings onto further experimentation 
firstly in vitro and then ideally into clinical trials.  
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7.2.1 Translational implications 
These results, if extrapolated, can offer exciting implications in the clinic, obviously there is 
further work to be performed to ensure its safety and efficacy (discussed later). However, initial 
and ground-breaking results are indeed encouraging. There are several features presented 
within the results that deserve highlighting. 
7.2.1.1 Gemcitabine-loaded SPIONs are of interest in size 
The completed nano-complex manufactured are consistently shown to be less than 200nm, even 
with an IgG antibody attachment. It is well known concerning the molecular biology of 
pancreatic ductal adenocarcinoma (PDAC), there is a dense peripheral stroma [74, 76, 78]. As 
a result, chemotherapy drug delivery to a tumour load in PDAC is challenging due the fibrotic 
stroma. The nano-complexes manufactured are of small enough size to potentially penetrate 
this dense surrounding peri-tumoural tissue and deliver its payload. This effect tried to be 
replicated when SPIONs were exposed to tightly formed spheroids, more in keeping with a 
solid tumoural mass. The SPIONs were successful in destroying the spheroids. 
7.2.1.2 Antibody targeting  
In these experiments, the anti-CA 19-9 antibody was used, as it is expressed in several PDAC 
types and is widely available, to showcase the active targeting effects. We found that to achieve 
the same reduction in cell viability of cancer cells, a significantly lower amount of drug 
concentration was required when using antibody-conjugated SPIONs compared to when 
SPIONs with no antibody attachment was used. The attached antibody in certain nano-
complexes produced, offer a specific targeting ligand that, like the results presented in vitro, 
could improve specificity in delivery chemotherapy drugs to desired cells or tissues in vivo. It 
offers a strategy for reduced unwanted systemic side effects in certain antigen expressive 
cancers. This lies within the concept of personalised medicine, where in an individual’s certain 
tumour is fully genotyped with complete immunohistochemistry in order to investigate any 
potential targetable biomarkers (such as antigens like CA 19-9); with that information nano-
complexes can be conjugated with target ligands specific to that tumour. Of interest, any IgG 
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antibody could be attached to the manufactured nano-complexes with the same chemistry 
process that I performed.   
7.2.1.3 Magnetic targeting 
As presented the cellular damage caused when the SPIONs were deployed with a magnetic 
field was most effective at early time points within the flow system. Furthermore, it was 
effective against negatively antigen expressive cells. The implications of this significant 
moving forward to in vivo work. As the preferred route of administration of SPIONs in currently 
via the intravenous route, the artificial circulation model was constructed to mimic blood flow 
and it is encouragingly that the SPIONs were still able to exert their effects successfully. When 
considering the results for translational purposes, it shows that SPIONs could be injected with  
the use of an implantable magnet or even a targeted magnetic field from a supermagnet, for a 
short period of time, reducing the exposure of chemotherapy drug concentration and subsequent 
side effects, before the magnet field is withdrawn. If an external magnet field is used, repeated 
administrations would be achievable being a non-invasive approach. 
 
7.3 Limitations 
However, encouraging the results presented are, they naturally only represent a small example 
in the vast field of nanoparticle-driven drug delivery to cancer. The major limitation in 
formulating translational implications from these experiments is that they have been performed 
in vitro and obvious cannot replicate the real-life conditions found within complex pancreatic 
tumours and the blood stream. 
7.3.1 Pancreatic cancer cells 
As the experiments performed were novel, optimisation was challenging. We were successful 
in manipulating two cell cancer lines BxPC-3. Obviously, it is well known that PDAC is a 
complex and heterogenous tumour with a surrounding stroma, that is not fully understood in its 
mechanism. These experiments were unable to replicate the elaborate nature of a PDAC, as the 
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SPIONs were tested against a homogeneous mass of cancer cells only. Nevertheless, attempts 
were made to mimic a solid tumour using the 3D models. Notably, the absence of any stroma 
replication is important, as it contains several components, including pancreatic stellate cells 
and growth factors, that may interact with the SPIONs and alter their behaviour. 
7.3.2 Artificial circulation 
Obviously, within an in vitro setting, we attempted to reproduce blood/plasma flow conditions 
that may be faced in vivo, by manufacturing an artificial system. The continuous flow contained 
media, which was proven not to be detrimental to the SPIONs. However, within the body, 
plasma contains a multitude of different components, which influence the pharmacokinetics of 
SPIONs greatly. For example, studies have demonstrated SPIONs are predominantly taken up 
by phagocytes in the reticuloendothelial systems of the liver, spleen, and lymph tissue [31], 
which obviously, the SPIONs used in our experimentation were not exposed to. 
7.3.3 Excretion and toxicity profile 
As the SPIONs were not tested against a biological system, its harmful effects cannot be 
examined. Therefore, its safe excretion and toxicity cannot be assessed here. 
7.3.4 CA 19.9 antigen expression 
Further to previous discussion, PDAC remains a complicated reality. There are multiple cell 
types with a several expressing proteins or biomarkers of interest. Although, CA 19-9 antigen 
remains the commonest biomarker of interest in PDAC, it is by no means universally expressed. 
Within tumours there is a variable degree of expression, if at all, like immortalised pancreatic 
cancer cell line. In the results, non-CA 19-9 expressive Mia Pa Ca-2 cells showed no reduction 
in cell viability by active targeting using the conjugated antibody. Extrapolated, this indicates 
that if targeting PDAC, perhaps a variety of targeting ligands need to be attached onto the 
SPION to counter the variability of the tumoural mass. If only one targeting ligand, in this case 
CA 19-9 antibody, is conjugated there may only be a partial or indeed no increased effect of 
the active chemotherapy agent. Nevertheless, despite the above being stated, results using the 
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CA 19-9 conjugated gemcitabine-loaded SPION against Bx PC-3 cells (CA 19-9 expressive) 
were very promising and definitively deserves further investigation and testing. 
 
7.4 Recommendations 
The results presented are exciting, and due to their novel nature would almost certainly require 
much more investigation as findings are at a nascent stage, like most nanomedical work into 
cancer drug delivery.  
7.4.1 Further in vitro studies 
For completeness, exploration of both active targeting modalities – with an antibody and 
magnetic field – should be considered to understand if there is any benefit in even more 
accelerated reduction in cell viability, especially in a flow system. These experiments were 
attempted, although results are not shown as they were not successfully repeated, preliminary 
findings showed that the magnetic field drew the SPIONs very early on, negating any effect the 
targeting antibody had. However, these results are only anecdotal at best.  
7.4.2 In vivo studies: murine models 
Initial experimentation to further investigate the effects of SPIONs would best be suited using 
a mouse model, this would be predominantly used to build a toxicity profile for the 
manufactured gemcitabine-loaded SPIONs.  
7.4.2.1 Active targeting 
However, if the mice are transfected with pancreatic cancer cells and the tumours allowed to 
mature, a response to treatment with various conditions (including the gemcitabine-loaded 
SPIONs), can be measured. Below is an outline for proposed experimentation in a murine mode 
– figure 27 and table 13. 
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Figure 26: Outline of proposed murine experiment: measuring pancreatic tumour size in nu/nu xenograft 
mouse model after tail-vein injection of gemcitabine-loaded SPIONs. 
Table 13: Different conditions for proposed murine model. (SPIONs = superparamagnetic iron oxide 
nanoparticles) 
Again, any murine model would have limitations. The pancreatic tumours would again 
homogenous in nature, which against what is known about PDAC in the clinic. However, the 
mouse model would provide valuable information regarding the accumulation, biodistribution 
and excretion of the SPIONs, which would lead to a preliminary toxicity profile. The behaviour 
of the SPIONs in vivo would provide essential knowledge moving forward in eventual clinical 
work.  
 
The above is addressing one active targeting method, regarding the use of an external magnetic 
field, there are a variety of methods that could be explored. Most simply, a basic mouse model 
could be used, and a subcutaneous tumour may be matured. Then the macro- and microscopic 
response to the tumour of treatment with conditions as per table 13 but with or without an 
external magnet. This approach would confirm the accelerated tumour damage achieved with 
a magnet; however, it would not replicate features of a PDAC seen clinically. More 
sophisticated methods to determine the effects of a magnetic field are available. Chertok et al 
describe magnet targeting of SPIONs to brain tumours in a tailor-made rat model, a 1.8-fold 
increase in SPION concentration was seen after intra-arterial administration (carotid artery) 
compared to intravenous injection. Furthermore, SPION concentrations increased with longer 
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cancer cells 
via tail vein
Allow 
tumour to 
grow for 7 
days and 
measure 
size of 
tumour 
(calipers)
Inject 
condition 
via tail vein
Measure 
tumour size 
on a daily 
basis for 7 
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Condition Comment 
Non-gemcitabine-loaded SPIONs Negative control for assessment of toxicity 
Gemcitabine-loaded SPIONs  
Gemcitabine-loaded SPIONs with CA 19-9 
antibody tag 
Active targeting mechanism 
Gemcitabine  Positive control 
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exposure to the magnetic field [143]. Obviously, the intra-arterial route is invasive and 
clinically not preferred. For in vivo studies, the application of the magnetic field will possibly 
require several magnetic field forces targeting an area of the body as opposed to the 
unidirectional magnetic force used in experiments to date. 
 
However, imaging-guided techniques, which are non-invasive, may be preferred and as 
previously described SPION treatment can be combined with the use of magnetic resonance 
imaging (MRI) scanning. This would not only allow one to visualise tumour accumulation or 
biodistribution of SPIONs, but also measure cancer treatment response. 
7.4.3 Future considerations and clinical work 
There are substantial hurdles before any early phase clinical trials would be considered, as the 
manufactured SPIONs toxicity profile would have to be declared. Until this is completed, 
unfortunately, no clinical research can start. 
 
In the future, clinical work would ideally investigate the effects of the gemcitabine-loaded 
SPIONs against pancreatic tumours, most likely in the palliative setting initially (where 
gemcitabine is mostly used), whilst being to image the response simultaneously using MRI. 
How this is achieved would be either with gemcitabine-loaded SPIONs conjugated with an 
individualised specific target ligand bound to the drug vehicle; or using an external magnetic 
field. The magnetic field would either be in the form of an implantable magnet or an external 
stereotactic-like magnetic field using a supermagnet. It must be noted that it would be unlikely 
to offer invasive surgery to implant a magnet in the palliative setting. Whatever the active 
targeting method, it is likely to require repeat sittings. Finally, treatment response ideally would 
be imaged using MRI, to gauge the response of the treatment against the drug-loaded SPIONs, 
similar to current practice in several solid tumours following initiation of a chemotherapy 
regimen. 
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7.4.3.1 Personalised nanomedicine 
It is increasingly clear that no two pancreatic tumours are the same. Current and future work 
will certainly focus on the individual’s tumour and consider a personalised approach to the 
patient’s treatment. As further research reveals more biomarkers and potentially ‘drug-able’ 
targets, especially from the abundance of cells from the stroma of a pancreatic tumour, it offers 
further hope to manufacture tailor-made nanoparticle-based drug delivery systems.  
7.4.3.2 Translational goals 
This is a completely novel project and potentially has very exciting and wide-ranging 
consequences. The data gathered from the project will inevitably add considerable knowledge 
to the potential effectiveness of nanoparticle-based chemotherapy, not exclusive to pancreatic 
cancer treatment. The concepts being tested in these experiments can be transferred to the 
treatment to other solid cancers. That is to say, an appropriate chemotherapy agent can be 
chemically loaded onto a nanoparticle complex with a suitable ligand (such as an expressed 
antibody) to target a specific cancer. These theories lead to the overall translational goal of this 
research, which is to be able to safely administer the manufactured nanoparticles in patients, 
with the capability to kill cancer cells without damaging normal, healthy cells, which causes 
unwanted effects from conventional chemotherapy. There is a huge potential to improve 
patients’ quality of life, by providing a more precise or personalised approach to the 
chemotherapy they receive. 
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8 Conclusions 
Pancreatic cancer therapy has poor outcomes despite advancement of chemotherapy agents and 
surgical interventions. There are a multitude of factors that have maintained the dismal 
prognosis over the past forty years. Drug delivery of cytotoxic drugs is a major factor. This is 
in part due to the hostile tumour microenvironment and complex stroma-tumour interactions. 
This indicates that newer approaches are desperately required in the delivery of anticancer 
drugs, this research demonstrates initial effective concepts to try to address the issues outlined.  
 
 
This project has shown that a stable and sophisticated SPION complex has been created and its 
effects tested on a variety of cellular models, confirming their desired effects. Furthermore, two 
methods of actively targeting the SPION have also been demonstrated: using an antibody and 
a magnet. Very encouraging results have been presented in 2D and 3D culture and finally with 
an artificial circulatory model. Although, the field of nanotechnology is booming there has been 
few applications towards the treatment pancreatic cancer. This is undoubtedly due to the 
exhaustive level of prior research and development required before even considering clinical 
use. Nevertheless, the results will add to the promising nascent work in the field of nanoparticle-
driven cancer therapy.
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